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1. 
ANALOGUES OF (-)-PICROPODOPHYLLIN, 
SYNTHESIS AND USES THEREOF 
CROSS-REFERENCE TO RELATED 
APPLICATION 
This application is a continuation of International Appli 
cation PCT/US09/033,416, filed Feb. 6, 2009 and also claims 
priority to U.S. Provisional Patent Application Ser. No. 
61/027,459, filed Feb. 9, 2008 and U.S. Provisional Patent 
Application Ser. No. 61/122,945, filed Dec. 16, 2008, the 
contents of which are hereby incorporated in their entireties 
herein. 
GRANT INFORMATION 
The subject matter of this application was developed at 
least in part under National Institutes of Health Grant No. 
NIH/1 PO1CAO97403, so that the United States Government 
has certain rights herein. 
SEQUENCE LISTING 
The specification further incorporates by reference the 
Sequence Listing submitted herewith via EFS on Feb. 20. 
2009. Pursuant to 37 C.F.R.S 1.52(e)(5), the Sequence Listing 
textfile, identified as “0700503731.TXT,” is 1,3661 bytes and 
was created on Feb. 20, 2009. The Sequence Listing, elec 
tronically filed herewith, does not extend beyond the scope of 
the specification and thus does not contain new matter. 
1. INTRODUCTION 
The invention relates to (-)-picropodophyllin analogues, 
methods of synthesizing said analogues and uses thereof. In 
certain non-limiting embodiments, the invention provides for 
methods of treating cancers using (-)-picropodophyllin ana 
logues, including basal-like cancers of the breast. 
2. BACKGROUND OF THE INVENTION 
The compound (-)-picropodophyllin binds tightly to the 
human Insulin-like Growth Factor I Receptor Kinase (IGF1 
RK) domain and inhibits its kinase activity. Such binding has 
the effect of inhibiting the anti-apoptotic signal pathways that 
are associated with IGF1 RK activity. This inhibition tends to 
decrease cancer cell growth and may also render cancer cells 
more Susceptible to chemotherapy. Importantly, the com 
pound, (-)-picropodophyllin, shows exquisite selectivity for 
the IGF1 RK over the structurally highly homologous Insulin 
Receptor Kinase (IRK) domain, the inhibition of which 
would give an undesired diabetes-type phenotype. This selec 
tivity could lead to a new class of chemotherapeutic drugs. 
At present, there is no drug on the market that acts upon the 
IGF1 RK. Development of such a drug is, therefore, an 
emerging macromolecular target of great current interest in 
the pharmaceutical community. 
Human breast cancers have been molecularly classified by 
gene expression profiling into three major Subtypes: luminal, 
ERBB2+ and basal-like. The luminal cancers are estrogen 
receptor-positive (ER+), whereas the cancers of the other two 
classes, which either overexpress ERBB2(HER2/NEU) or 
exhibit phenotypic features of basal/myoepithelial cells, are 
ER-negative (Perou et al., Nature (2000), 406, 747-52: Sorlie 
et al., Proc. Natl. Acad. Sci. U.S.A. (2001), 98, 10869-74; 
Sorlie et al., Proc. Natl. Acad. Sci. U.S.A. (2003), 100, 8418 
23). Basal-like cancers also lack progesterone receptor (PR) 
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2 
and ERBB2 (ER-/PR-/ERBB2-; “triple negative breast can 
cers'), but frequently express EGFR and basal markers, such 
as cytokeratins 5/6 and/or 14 and p63 (Nielsen et al., Clin. 
Cancer Res. (2004), 10, 5367-74). The basal-like class (15 
20% of all breast cancers; recently reviewed by Yehiely et al., 
Trends Mol. Med. (2006), 12, 537-44; Finnegan and Carey, 
Future Oncol. (2007),3,55-63; DaSilva et al., J. Clin. Pathol. 
(2007), 60, 1328-32) includes high proportions of BRCA1 
associated and also medullary and metaplastic Subtypes. The 
latter group is heterogeneous and consists of squamous and 
spindle cell carcinomas and other forms. Basal cancers 
appear to have extremely bad prognosis (Sorlie et al., Proc. 
Natl. Acad. Sci. U.S.A. (2001), 98, 10869-74), especially in 
the early years of follow-up after diagnosis and treatment, 
although this was not clearly evident in some patient cohorts 
(Chin et al., Cancer Cell (2006), 10, 529-41). In addition, 
these aggressive cancers pose a serious problem to targeted 
therapies, considering that the use of antiestrogens in combi 
nation with an anti-ERBB2 antibody (trastuzumab) is not an 
option, while there is no clear choice for chemotherapeutic 
intervention (see, for example, Cleator et al., Lancet Oncol. 
(2007), 8, 235-44; Carey et al. Clin. Cancer Res. (2007), 13, 
2329-34). 
Interestingly, an association between basal cancers and 
Kras amplification is now emerging. Ras-family members, 
apparently serving overlapping but also distinct cellular func 
tions, act as molecular Switches in signaling pathways regu 
lating proliferation or apoptosis, and become constitutively 
active and, thus, oncogenic by mutation (usually at codons 12, 
13 or 61). Although Kras is overall the most frequently 
mutated isoform, there is tissue-specificity and variable inci 
dence of mutations in Ras tumorigenic action, as different 
human tumors harbor different mutant family members. In 
contrast to pancreatic ductal adenocarcinoma, in which Kras 
mutations (most commonly in codon 12) can be found at 
frequencies as high as 90% (Almoguera et al., Cell (1988), 53. 
549-54), the incidence of Kras mutations in breast cancer 
appears to be low (~7% on average; reported frequencies of 
/40, /25, 3/61 and 3/10; Rochlitz et al., Cancer Res. (1989), 49. 
357-360; Prosperi et al., Cancer Lett. (1990), 51, 169-74) 
Myaikas, et al. Biochem. Biophys. Res. Commun (1998), 251, 
609-612: Chen, et al., Cancer Lett., (2005), 229, 115-22). In 
human breast cancer cell lines, however, the observed fre 
quency was higher (~13%; 5/40: Hollestelle et al., Mol. Can 
cer. Res. (2007), 5, 195-201). Signaling elicited by non-mu 
tated, but overexpressed Ras can also collaborate with other 
deregulated pathways in tumor progression and invasion 
(Clark and Der, Breast Cancer Res. Treat. (1995), 35, 133 
44). For example, incomparison with control breast tissue, 11 
of 20 breast cancers exhibited a 2- to 6-fold increase in enzy 
matically measured Ras activation (relative amount of GTP 
bound form; von Lintig et al., Breast Cancer Res. Treat. 
(2000), 62, 51-62), while Western analysis indicated that in 
~70% of primary breast cancer specimens (n=132) the level 
of Ras was higher than in normal breast tissue (Dati et al., Int. 
J. Cancer (1991), 47,833-38). Notably, in 56% (9/16) of exam 
ined basal-like human breast cancers identified by expression 
profiling, the Kras locus was amplified and, thus, overex 
pressed (Herschkowitz et al., Genome Biol. (2007), 8, R76). 
The IGF signaling system, which is the major determinant 
of mammalian organismal growth (Efstratiadis A Int. J. Dev. 
Biol. (1998), 42:955-976), has also been implicated in the 
pathogenesis of various human cancers (Pollak MN, et al., 
Nat. Rev. Cancer (2004), 4:505-518.), including breast 
tumors (Sachdev D and Yee D. J. Mammary Gland Biol Neo 
plasia (2006), 11:27-39). A seminal observation, in this 
regard, was that cells lacking Igflr, the tyrosine kinase recep 
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tormediating the effects of insulin-like growth factors, cannot 
be transformed by any one of several tested oncoproteins 
(Sell C, et al. Proc. Natl. Acad. Sci. USA (1993), 90:11217 
11221; Sell C, et al. Mol. Cell. Biol. (1994), 14: 3604-3612: 
Baserga R, Expert Opin. Ther. Targets (2005), 9:753-768). 
Signaling through Igflr does not appear to be an oncogenic 
component perse, but a crucial prerequisite for tumorigenesis 
because, among other actions such as the promotion of cel 
lular proliferation by stimulation of the Ras/MAPK/ERK 
pathway, it exerts strong PI3 kinase-dependent and indepen 
dent antiapoptotic effects that are necessary for tumor growth 
(Baserga R, Expert Opin. Ther. Targets (2005), 9:753-768). 
Moreover, the IGF system appears to be involved in resistance 
to certain anticancer regimes (Ryan P D and Goss P E. 
Oncologist (2008), 13:16-24). On the basis of these consid 
erations, potential therapeutic approaches for cancer treat 
ment involving blocking of IGF signaling with Small mol 
ecules or antibodies are currently under development 
(Sachdev D and Yee D. J. Mammary Gland Biol Neoplasia 
(2006), 11:27-39; Baserga R. Expert Opin. Ther: Targets 
(2005), 9:753-768; Ryan P D and Goss P E. Oncologist 
(2008), 13:16-24; Garcia-Echeverria C. IDrugs (2006), 
9:415-419; Hartog H, et al., Eur: J. Cancer (2007) 43:1895 
1904). 
3. SUMMARY OF THE INVENTION 
The present invention provides for compounds, composi 
tions, methods of making, and methods of using analogues of 
(-)-picropodophyllin, as well as a transgenic animal model 
and its use for identifying anticancer agents. It is based, at 
least in part, on the discoveries that (i) Igflr was overex 
pressed in mammary tumors advantageously induced 
extremely rapidly by oncogenic Kras in a mouse model, and 
(ii) breast-specific genetic ablation of Igflr expression dem 
onstrated that the cognate signal transduction pathway is 
causally involved in tumorigenesis. 
In particular non-limiting embodiments, the present inven 
tion provides for methods of treating a cancer in a subject 
comprising administering, to the Subject, an effective amount 
of an analogue of (-)-picropodophyllin. In particular, non 
limiting embodiments, the cancer cells demonstrate a muta 
tion in Kras. In a specific, non-limiting embodiment, the 
cancer is a basal-like cancer of the breast. 
4. BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1A-D. Application of a general method for tissue 
specific expression of oncoproteins in mice. (A) Inserts (in 
pBSK) or two plasmids used for construction of a targeting 
vector for knock-in of a chosen cDNA into the Eefla locus 
("Eeflal cassette'). The first plasmid consists of a splice 
acceptor site (0.2 kb), a floxed segment that includes a neo 
selectable marker (0.8 kb) linked to a “stop” sequence (SX 
pA: triple polyA, 1.5 kb), and a polylinker (multiple cloning 
sites; MCS) followed by an additional polyadenylation signal 
(pA: 0.25 kb). A chosen cINA is cloned into the MCS, and 
then the entire compound insert is excised by digestion with 
PacI and AscI and cloned into the corresponding sites of the 
second plasmid that provides 5' and 3' homology arms to the 
final targeting vector. The engineered PacI and AscI sites 
(separated by a PmeI site) have replaced a Spel site in the first 
intron of Eefla1. The experiments described herein utilized 
an older version of the first plasmid, in which the neogene 
was driven by the Pgk promoter. (B) Homologous recombi 
nation in ES cells ("knockin': indicated by X symbols) using 
a targeting vector that was constructed by inserting into the 
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MCS of the Eefla cassette an oncogenic Kras cDNA. A 
simplified restriction map and the noncoding and coding 
exons of the locus (open or filled rectangles, respectively) are 
indicated. Excision of the “floxed’ block from the targeted 
allele by Cre-mediated recombination (using in this case a 
Wap-cre transgene for specific expression of the recombinase 
in mammary glands) allows excision of the “stop” sequence 
and consequent Kras transcription driven by the Eefla pro 
moter. (C) Molecular analysis. Southern analysis was per 
formed using EcoRV-digested DNA that was extracted in the 
examples shown either from tails of a wild-type or a trans 
genic animal, or from a Kras-induced tumor that developed 
after Wap-cre-mediated recombination. Northern analysis 
shows that, in addition to the two endogenous Kras mRNAs 
which are transcribed from the intact allele in wild-type mam 
mary glands (MG), the targeted allele expresses in tumors two 
new Kras transcripts (marked by asterisks in the figure). 
Western analysis using an antibody recognizing the Kras4B 
isoform encoded by Kras indicates that the amount of the 
oncoprotein is significantly higher in mammary tumors than 
in normal glands. (D) Kaplan-Meier tumor-free mouse Sur 
vival curves. The survival of female mice from the day of the 
first parturition until the day of detection of palpable Kras 
induced tumors is compared between animals carrying the 
oncogenic transgene either in the presence of wild-type Igflr 
or in a genetic background in which one or both floxed Igfr1 
alleles have been conditionally ablated. In mice possessing at 
least one intact Igfr1 allele, tumors appear immediately after 
a single pregnancy, in contrast to the animals with Igfr1 
nullizygous mammary epithelial cells (three pregnancies). 
FIG. 2A-C. Histology and immunophenotyping of mam 
mary carcinomas. (A) Krasi-induced mouse mammary 
tumors exhibit four histopathological forms. The insets in the 
H&E-stained sections (first row) show CISs of the corre 
sponding invasive carcinomas. For details about the immun 
ostaining results, see Example3 and Table 4. (B)Examples of 
mouse and human pale breast cancers. A mouse Kras-in 
duced pale cell carcinoma exhibits a strong histological simi 
larity (H&E staining) with a specimen of human atypical 
medullary breast cancer and both tumor types are strongly 
positive for Igflr immunostaining. (C) KRAS copy gains in 
Some atypical medullary breast cancers with pale cells. The 
dual color FISH analysis using KRAS (red/lighter) and chro 
mosome 12 centromeric (green/brighter) probes shows that, 
in cells from three different human pale breast cancer speci 
mens (the right panels are from the same tumor), there are 
copy gains of the 12p12.1 region (up to 6 KRAS copies). 
FIG. 3A-F. Drug treatment of Kras-induced mammary 
carcinomas. Examples of tumor development in mice carry 
ing an activated Kras oncogenic transgene, which were 
injected either with vehicle (“V”, panels A, C and E) or with 
picropodophyllin (“PPP, designated “P” in the figure, panels 
B, D, and F). Examination of tumors macroscopically (A, B) 
and histologically (C, D) after three weeks of treatment 
showed that, in comparison with the controls (A and C. 
vehicle), the PPP-treated tumors were dramatically smaller 
(B and dotted circles in D). Compared to vehicle (E), admin 
istration of PPP for 3 days increased -9-fold the level of 
apoptosis detected in the pale component, as assayed by 
activated caspase 3 immunohistochemistry (brown staining). 
Scale bar-1.0 cm (A and B); scale bar 5.0 mm (C and D). 
Original magnifications: x20 (C and D); x400 (E and F). 
FIG. 4A-F. Effects of PPP administration for 3 weeks (P: 
panels B, D and F) compared to vehicle injection (V, panels A, 
C and E) on the components of Kras-induced carcinomas. 
The PPP treatment diminishes the size of pale cell tumors (B. 
dotted circles) and results in extensive keratinization (D) and 
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Vaculolation (D inset) of the squamous component. Original 
magnifications: x200 (A-D); x40 (D inset); x400 (E. F). 
FIG. 5A-G. Similarity of mouse and human pale breast 
cancers. A mouse Kras-induced pale cell carcinoma (A) 
exhibits a strong histological similarity (H&E staining) with 
an example of a human atypical medullary breast cancer (C) 
and both tumor types (B and D, respectively) are strongly 
positive for Igflr immunostaining. The dual color FISH 
analysis using KRAS (red) and chromosome 12 centromeric 
(green) probes (panels E, F and G: individual cells from three 
different human pale breast cancer specimens like the one in 
C) shows amplification of the 12p12.1 region (up to six 
KRAS copies). 
FIG. 6. Immunophenotyping of Kras-induced mouse 
mammary carcinomas (Part II). 
FIG. 7. Hierarchical clustering of genes (rows) and speci 
mens (columns). The dendrogram shown (derived by unsu 
pervised analysis using CYG WIN software) reveals that there 
is clear discrimination in gene-expression patterns between 
normal (WT) mammary glands and tumor specimens strati 
fied according to the degree of their enrichment in one of the 
three basal-like components (sarcomatous, SRC, squamous, 
SCC; and pale, PCC). A scale is shown on the right. 
FIG. 8A-C. In vitro inhibition of Igflr action. Representa 
tive experiments of pharmacological inhibition of IGF1R in 
MDA-MB-231 cells by picropodophyllin (A) or by IGF1R 
knockdown using a dominant-negative construct (B) or 
siRNA (C). The absorbance (mean values+S.E.M.) reflects 
cell numbers estimated from duplicate samples using the 
MTT assay (see Experimental Procedures). (A) MDA-MB 
231 cells were seeded in 24-well plates at 10% confluence 
(day 0) and treated with vehicle (DMSO: final concentration 
0.1%) or PPP dissolved in DMSO (final concentration 500 
nM). (B) Plasmid 486Stop (encoding dominant-negative 
IGF1R) or a control plasmid (pcDNA3) were introduced in 
MDA-MB-231 cells by nucleofection following the manu 
facturer's protocol (1.5 g of plasmid DNA per 106 cells; 
Amaxa Biosystems). The same method was used to introduce 
into these cells a 19-bp RNA duplex (R4) targeting IGR1R 
mRNA or a scrambled control duplex (Scra; see SI Materials 
and Methods, for details). The efficiency of nucleofection 
under our conditions (estimated by adding to the samples a 
GFP-expressing plasmid) was ~60%. 
FIG. 9. Example of FACS Analysis of Mammary Cell 
Suspensions. Cells were isolated from normal mammary 
glands of parous animals or from invasive mammary carci 
nomas that developed in mice carrying a Kras oncogenic 
transgene. Flow-sorting of progenitor cell populations was 
performed as described (Stingl, J. et al. Nature (2006), 439: 
993-997). The MRU fraction (mammary repopulation units) 
is enriched in mammary stem cells, whereas the Ma-CFC 
fraction (mammary colony-forming cells) is enriched in 
luminal cell precursors. Ma-CFCs are CD24" CD49f", 
whereas MRUs are CD24" CD49f's". The percentages of 
cells in these populations are indicated. 
FIG. 10. Localization of integrins C6 (CD49f) and B1 
(CD29). The distribution of Itgaé and Itgb1 in normal mam 
mary glands and in the four histopathological forms of Kras 
induced invasive carcinomas was determined by double 
immunofluorescence using the antibodies listed in Table 9. 
Both markers were found co-localized in the basement mem 
brane of the myopithelial layer in normal glands. Itgb1 was 
also present in the basolateral, but not the luminal aspect of 
luminal cells. This distribution was maintained in microaci 
nar adenocarcinomas, but only for Itgb1, whereas the basal 
like forms had altered patterns. Thus, all SCC cells exhibited 
intense labeling for both markers co-localized circumferen 
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tially, while the intensity of signal in PCC and SRC was 
variable and did not involve all cells. 
5. DETAILED DESCRIPTION OF THE 
INVENTION 
The invention provides inhibitors of IGF1RK as well as 
methods of synthesizing the inhibitors and using them thera 
peutically. As therapeutics, these Small molecules have 
advantages over antibodies, including circumventing pos 
sible immune responses associated with the latter, as well as 
permitting oral administration and potentially increasing bio 
logical half-life. Production cost is also likely to be much 
lower. 
An aspect of the invention is directed to analogues and a 
method for the synthesis of analogues of the natural product 
(-)-picropodophyllin with control of both absolute and rela 
tive stereochemistry. Absolute and relative stereochemistry 
are important for biological activity in lignans. 
MeO OMe 
OMe 
(-)-picropodophyllin 
Thus, (-)-podophyllotoxin, the C-2-epimer of (-)-pi 
cropodophyllin, features a structurally distinct trans-fused 
lactone in the D-ring. (-)-Podophyllotoxin acts as an anti 
mitiotic and does so by binding tightly to tubulin, thereby 
preventing its polymerization in spindle formation. The struc 
ture of the (-)-podophyllotoxin-tubulin complex has been 
established by X-ray crystallography. 
If one inverts the C-4 center one arrives at the family of 
epipodophyllotoxins i.e. epimers at both C-2 and C-4 of 
(-)-picropodophyllin, including etoposide, teniposide, and 
TOP-53. These compounds act by binding to the enzyme 
topoisomerase II and inhibiting the religation step along the 
enzymatic reaction coordinate. This leads to a build up of a 
covalent enzyme-DNA complex that serves as a cellular sig 
nal, triggering apoptosis. 
Thus, while members of all three of these lignan families 
are of interest as potential medicinal agents, if one wishes to 
develop chemotherapeutics that target the IGF1 RK, control 
of stereochemistry is important, and represents an important 
feature of this invention. 
The natural product (-)-picropodophyllin is shown above 
as 1. 
Aspects of the present invention are directed to analogues 
of (-)-picropodophyllin having modified E-rings as shown 
below in formula I. 
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Many types of substitutents are available for ring Edue to 
the late addition of ring E during synthesis of the compounds. 
X, X'.Y.Y. and Zare ring E substituents and X, X', Y.Y. and 
Z may be independently hydrogen; deuterium; tritium; a 
C-C saturated or unsaturated, alkyl or cycloalkyl group; a 
hydroxyl group; an ether-protected hydroxyl group bearing a 
C-C Saturated or unsaturated alkyl or cyclic alkyl group; a 
carboxylate ester-protected hydroxyl group derived from a 
C-C Saturated or unsaturated, cyclic or acyclic, carboxylic 
acid; a hydroxyl group protected as a phosphate mono-, di- or 
triester, the di-, or triester having C-C Saturated or unsatur 
ated alkyl group(s): a C-C alkoxy, a C-C alkoxy, a phos 
phonate mono- or diester-protected hydroxyl group derived 
from a C-C saturated or unsaturated, cyclic oracyclic, phos 
phonic acid wherein the diester also contains a C-C Satu 
rated or unsaturated alkyl group; a phosphinate ester-pro 
tected hydroxyl group derived from a phosphinic acid bearing 
two C-C Saturated or unsaturated, cyclic or acyclic, alkyl 
groups; a hydroxyl group protected as a Sulfate mono- or 
diester bearing a C-C Saturated or unsaturated alkyl group; 
a hydroxyl group protected as a Sulfonate ester derived from 
a Sulfonic acid bearing a C-C Saturated or unsaturated, 
cyclic or acyclic, alkyl group; an amino group; a primary or 
secondary amine bearing 1 to 2 C-C Saturated or unsatur 
ated alkyl group(s), respectively; a carboxamide-protected, 
unsubstituted or primary amine bearing a C-C Saturated or 
unsaturated alkyl group; an amino group derived from a 
C-C Saturated or unsaturated, cyclic or acyclic, carboxylic 
acid; a carboxylic acid; a carboxylate ester bearing a C-C, 
saturated or unsaturated alkyl group; a phosphonic acid; a 
phosphonate mono- or diester bearing 1 to 2 C-C Saturated 
or unsaturated alkyl group(s), respectively; a phosphinic acid 
having a C-C saturated or unsaturated, cyclic or acyclic, 
alkyl group or ester bearing a C-C Saturated or unsaturated 
alkyl group; a formyl group; an acetyl group; a benzoyl 
group; a carboxamide group derived from ammonia or from a 
primary or secondary amine bearing 1 to 2 C-C Saturated or 
unsaturated alkyl group(S), respectively; a sulfhydryl group; a 
thioether bearing a C-C Saturated or unsaturated, cyclic or 
acyclic, alkyl group; a Sulfonic acid, a Sulfonate ester bearing 
a C-C Saturated or unsaturated alkyl group; an alkylsulfonyl 
group bearing a C-C Saturated or unsaturated, cyclic or 
acyclic, alkyl group; a phenylsulfonyl group; a Sulfoxide 
bearing a C-C Saturated or unsaturated, cyclic or acyclic, 
alkyl group; a phenylsulfoxide; a phenylseleno group; a phe 
nylselenoxide; an azide; a halogen; a cyano group; a nitro 
group; a nitroso group; a diazonium group; or a trifluorom 
ethyl group with the proviso that when X and X’ are H.Y.Y", 
and Z cannot all be methoxy. 
In further aspects, X, X, Y, Y and Z are independently 
hydrogen, a C-C alkyl or C-C alkoxy group. In further 
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aspects, X, X', Y.Y. and Z are hydrogen, methyl, or methoxy 
with the proviso that when X and X’ are H.Y.Y', and Z cannot 
all be methoxy. 
In further aspects, the present invention is directed to (-)- 
picropodophyllin analogues with modified E-rings as shown 
below. 
Wherein 
(1) X, X, Y, Y-H, and Z=OCH (compound 19, below) 
(2) X, X, Y, Z=H, and Y=OCH: 
(3) X, X, Y, Z=H, and Y—OCH (compound 18, below) 
(4) X, X", Y-H, and Y, Z=OCH: 
(5) X, X', Y=H, and Y, Z=OCH (compound 20, below) 
(6) X, X', Z=H, and Y.Y'—OCH (compound 21, below) 
(7) X, X, Y, Y-H, and Z=CH, 
(8) X, X, Y, Y-H, and Z=CH, C(4)-epimer-4-epi-pi 
cropodophyllin analaogue) 
The present invention is also directed to enantiomerically 
enriched compounds which do not occur naturally and are not 
readily available from (-)-picropodophyllin. Enantiomeri 
cally enriched means that the enantiomeric ratio is at least 
95:5, preferably at least 97:3, prior to recrystallization. 
The present compounds may be prepared by first preparing 
a compound of formula (a) by any suitable means such as 
starting from readily available piperonal, utilizing (i) bromi 
nation, (ii) acetalization and (iii) installation of a hydroxym 
ethyl group (halogen/metal exchange and aryllithium trap 
ping with paraformaldehyde). 
In the presence of acetic acid, formula (a) cyclizes and, 
upon losing two molecules of MeCH, transiently provides the 
highly reactive isobenzofuran (b), which reacts, in situ, via a 
Diels-Alder reaction with DMAD (dimethyl acetylenedicar 
boxylate) to form Diels-Alder adduct (c). 
OMe 
K OMe -----> 
OH 
O 
(a) 
-N (OMe 
O e { o || -- O S. 
(b) N-1 O.Me 
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O 
O 
OMe 
A. D 
O OMe 
O 
(c) 
Diels-Alder adduct (c) can be selectively hydrogenated, 
reduced to the diol with LiAlH4 and acetylated to provide 
meso diacetate (d). 
O 
K OH 
O OAc 
The achiral and symmetrical system bearing all carbons of 
the target cyclolignan A-D rings is efficiently desymmetrized 
with porcine pancreatic lipase (PPL) to produce (e) in syn 
thetically useful enantiopurity level. 
The compound of formula (e) is subjected to silylation, 
deacetylation, and oxidation to produce a compound of for 
mula (f) without loss of optical activity. Sillylation occurs with 
a silylating agent, RX, including but not limited to TIPSC1 
(triisopropylsilyl chloride), TBDMSC1 (tert-butyldimethylsi 
lyl chloride), and TBDPSC1 (tert-butyldiphenylsilyl chlo 
ride), in the presence of an appropriate base Such as imidazole 
or NEts. Deacetylation is carried out under standard condi 
tions (e.g. EtO, NaHCO, or KCO, MeOH or Na, MeOH or 
NH, MeOH.) The aldehyde is then oxidized under mild 
two-electron oxidation conditions (e.g. Swernor Moffattoxi 
dation (DMSO as oxidant), Ley oxidation (TPAP tetrapro 
pylammonium perrhuthenate as oxidant) or Dess-Martin oxi 
dation (Dess-Martin periodinane as oxidant.)) 
O CHOR 
{ 
O CHOH 
(f) 
R is a silyl protecting group such as a triisopropylsilyl 
protecting group. 
The compound of formula (f) is converted to a compound 
of formula (g) by retro-Michael ring opening and protection 
of the C OH followed by aldehyde oxidation. The ring 
opening occurs under typical Michael addition conditions 
(such as NaOMe and MeOH). The protection step must be 
carried out under neutral to basic conditions (to avoid aroma 
tization). Use of a silyl (such as TES=triethylsilyl)ether pro 
tecting group for the C-4 hydroxyl is an advantageous feature 
of the present invention. This sets the stage for an efficient 
desilylative lactonization at the close of the synthesis, unveil 
Her 
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ing the (-)-picropodophyllin core in a single operation, 
immediately following the stereocontrolled installation of 
ring E. 
Aldehyde oxidation proceeds Smoothly under Lindgren 
conditions (NaClO, as oxidant) to give (g). The efficient 
retro-Michael ring-opening of (f) unveils the (methylene 
dioxy)cinnamyl system as the vehicle for late installation of 
ring E. 
(g) 
R10 
O CHOR 
O . 
R" is a C protecting group such as a triethylsilyl-protect 
ing group. 
The compound of formula (g) is converted to a compound 
of formula (h) by transformation of the carboxylic acid into an 
acyl oxazolidinone functionality. This requires carboxyl acti 
Vation (e.g. with carbonyl diimidazole) and then condensa 
tion with a metalated oxazolidinone to give (h). 
--- 
(h) 
CHOR 
( \, 
Y 
O O 
The Ering is introduced to the compound of formula (h) to 
form a compound of formula (I) by Cu'-mediated conjugate 
addition of RMgBr at a temperature of -10 to 10° C. 
(i) 
The compound of formula (i) is converted to a compound 
of formula () by desilylative lactonization by heating with a 
fluoride source and cyclization to produce the corresponding 
lactone; 
() 
R O 
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Non-limiting examples of Such syntheses are provided in 
Section 6. Example 1, below, the details of which are incor 
porated by reference in their entirety into this Section 5. 
Further aspects of the invention are directed to (-)-pi 
cropodophyllin analogues as shown below. 
II 
O 
wherein X, X,Y.Y', and Zare defined as above; R' may be 
oxo. —OH, -OCH —OCHs —OCH7, -OCH, 
–OCH-CH=CH, OCHPh, OCHCH-NH2, 
OCOH, OCOCH, OCH-OH, OCHOH, 
—OCHOH, -OCHOH, or a glycoside. In specific, non 
limiting embodiments, R' may be oxo, OH, OCH, 
—OCHs —OCH7, OCH —OCH-CH=CH, 
–OCHPh, OCHCH-NH, OCOH, OCOCH, 
–OCHOH, OCHOH, - OCHOH, - OCH-OH, or a 
glycoside and X, X, Y, Y and Z are selected from the group 
consisting of (1) X, X,Y.Y'—H, and Z—OCH; (2) X, X,Y, 
Z—H, andY—OCH; (3) X, X,Y,Z=H, andY—OCH; (4) 
XX,Y—H, and Y, Z=OCH; (5) X,X,Y-H, and Y, 
Z—OCH; (6) X, X', Z=H, and Y, Y-OCH; X, X, Y, 
Y—H, and Z=CH, and (8) X, X, Y, Y-H, and Z=CH, 
C(4)-epimer-4-epi-picropodophyllin analaogue). 
III 
wherein X, X', Y.Y', and Zare defined as above; RandR 
may be independently oxo. —OH, -OCH —OCHs. 
–OCH, OCH, OCH-CH=CH, OCHPh. 
OCHCH-NH OCOH, OCOCH, OCHOH, 
OCHOH, - OCHOH, - OCHOH, or a glycoside. In 
specific, non-limiting embodiments, R' and R may be inde 
pendently oxo, —OH, -OCH —OCHs —OCH7. 
—OCH, –OCH-CH=CH, OCHPh. 
–OCHCH-NH, OCOH, OCOCH, OCHOH, 
OCHOH, - OCHOH, - OCHOH, or a glycoside, and 
X, X'.Y.Y. and Zare selected from the group consisting of (1) 
X, X, Y, Y-H, and Z=OCH; (2) X, X, Y, Z=H, and 
Y—OCH; (3) X, X, Y, Z=H, and Y—OCH; (4) X, X', 
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Y-H, and Y, Z=OCH; (5) X, X,Y-H, and Y, Z–OCH: 
(6) X, X, Z=H, and Y, Y=OCH; X, X, Y, Y-H, and 
Z=CH and (8)X, X,Y, Y-H, and Z=CH, C(4)-epimer 
4-epi-picropodophyllin analaogue). 
Examples of suitable R' and R substituents include the 
substituents disclosed in U.S. Pat. Nos. 5,132,322; 5,300,500; 
5,332,811: 5,541,223; and 6,051,721 which are each incor 
porated herein by reference. 
Preferred, non-limiting embodiments of the invention 
include 5'-Didemethoxy-(-)-picropodophyllin (Compound 
18), 3',5'-Didemethoxy-(-)-picropodophyllin (Compound 
19), 5'-Demethoxy-(-)-picropodophyllin (Compound 20), 
and 4'-Demethoxy-(-)-picropodophyllin (Compound 21), 
the syntheses of which are described in the working 
examples. 
The effects of the compounds described above on activities 
of IGF1R can be determined in in vitro and in vivo assays, as 
described in the Examples below. Example 2 describes a 
method of monitoring the effect of compounds on cell 
growth. Inhibition of kinase activity of the IGF1R can be 
measured by any means known in the art. The kinase domain 
of the receptor is available from Upstate Biotechnology. 
In one embodiment, a cell line is used to assay the effects of 
these compounds on activities of IGF1R, for example, a 
murine breast cancer cell line derived from Kras mice. In 
one embodiment, the cell line is placed in a multi-well-plate, 
including, but not limited to a 24-well plate, and a 96-well 
plate. In one embodiment, cells contained in a Subset of wells 
are treated with a substrate, for example, a Substrate used in a 
calorimetric metabolic assay that reflects cell density, for 
example, MTT (Thiazol Blue Tetrazolium), and cells in 
another subset of wells are treated with an IGF1R inhibitor, 
for example, cyclolignan picropodophyllin (PPP), or the 
compound(s). The effectiveness of these compounds on 
activities of IGF1R is compared with that of a known IGF1R 
inhibitor, for example, PPP. 
The Kras mouse is a suitable in vivo model in which to test 
the effect of IGF1RK inhibitors on tumor growth (see 
Examples 3 and 4). The Kras mouse overexpresses a Kras2 
gene carrying the oncogenic Substitution G12D. The gene has 
been knocked-in into the highly and ubiquitously expressed 
locus Eefla. Cre-mediated removal of a STOP sequence 
residing upstream from the Kras cDNA allows for its tissue 
specific expression. Mice in which the oncogene is activated 
in the mammary epithelium by use of the WAPcre line 
develop tumors very rapidly (as early as 2 days upon partu 
rition; T50–9 days). Moreover, these tumors display high 
heterogeneity in histopathology. Four major patterns of inva 
sive carcinoma were detected (well differentiated glandular 
adenocarcinoma (Dunn A and B Tumors), pale cell carci 
noma, squamous cell carcinoma and spindle cell (sarcoma 
tous) carcinoma). In addition, histopathological characteriza 
tion of the tumors showed that, with the exception of the 
glandular adenocarcinoma, these tumors express basal mark 
ers and share great similarities in expression profiles with 
human and mouse basal-like breast cancers. Expression pro 
file analysis and immunophenotyping showed that the IGF1R 
was significantly overexpressed in the Kras-induced neo 
plasms. This is believed to be the first description of a mouse 
model in which a malignant neoplasm is induced by a single 
tumorigenic stimulus in one step without a requirement for 
secondary oncogenic events, as evidenced by the rapidity of 
tumor development. This unexpected observation can be 
attributed to the abnormally high expression levels of a pow 
erful oncogene. 
Accordingly, in one set of embodiments, the present inven 
tion provides for a system and a method for producing a 
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transgenic animal model of a human tumor, wherein a tumor 
in the transgenic animal is induced by expression of an onco 
gene operably linked to a Eefla (for Eukaryotic translation 
Elongation Factor 1 Alpha 1) promoter (e.g., the endogenous 
promoter), and expression of the oncogene is triggered by 
excision of a “stop’ (transcription termination) signal by 
Cre-mediated recombination. The oncogene may be intro 
duced into the Eefla 1 locus by “knockin' technology into an 
area of the gene Such that, after transcription, it will be trans 
lated. In one embodiment, a cDNA encoding the oncogene is 
inserted into an intron as part of a construct having a splice 
acceptor site (i) downstream of a “floxed’ stop signal and (ii) 
upstream of the cDNA coding sequence (to prevent the con 
struct sequence being spliced out from the mRNA precursor 
and lost during mRNA maturation); preferably, the construct 
is inserted into the first intron. However, the present invention 
also envisions inserting a construct comprising the cDNA 
encoding the oncogene into an exon of the Eefla locus, 
although this would be less desirable. In various embodi 
ments of the invention, the oncogene may be any oncogene 
known in the art, including but not limited to Kras and acti 
Vating mutations thereof (e.g., at codons 12, 13, or 61, e.g., 
G12D), Hras, c-myc, Her2/neu, Src, Wnt 1, PI3 kinase, etc. 
In non-limiting set of embodiments of the invention, an 
Eeflal cassette may be prepared comprising (from upstream 
to downstream) (i) a 5' arm homologous to the Eeflal site 
being targeted; (ii) a splice-acceptor site; (iii) a loXP site; (iv) 
a transcription termination signal (e.g., a multiple signal Serv 
ing, before its removal, as a block “STOP’’ sequence); (v) a 
loXP site; (vi) a multiple cloning site; (vii) a polyadenylation 
signal and (viii) a 3' arm homologous to the Eefla 1 locus 
targeted, further comprising a nucleic acid encoding a select 
able marker (e.g., neo), positioned upstream of the transcrip 
tion termination signal. Any gene of interest, including but 
not limited to an oncogene Such as Kras or an activated form 
thereof (designated “Kras' herein), may be inserted into the 
multiple cloning site. A non-limiting example of such a con 
struct is shown in FIGS. 1A and 1B. ES cells may be elec 
troporated with this cassette, expression of the selectable 
marker may be used to select for targeted cells, and integra 
tion at the correct locus may be confirmed by standard tech 
niques. An ES cell carrying the desired "knockin' transgene 
may then be used to produce a first transgenic animal that can 
transmit the genetic modification to its progeny. 
According to the present invention, a first transgenic ani 
mal carrying an Eeflal cassette described in the preceding 
paragraph may be mated with a second transgenic animal 
carrying a transgene comprising a Cre-gene operably linked 
to a promoter, where the promoter is either active or shows 
increased activity in a specific tissue, and/or at a specific 
developmental stage, and or under certain conditions (e.g., 
during late pregnancy and lactation, or in response to an agent 
Such as tetracycline or tamoxifen). Thus, an initially dormant 
oncogene present in the Eeflal cassette may be conditionally 
activated. In progeny animals carrying both the Eeflal cas 
sette and the Cre transgene, the nature of the Cre-linked 
promoter determines the site and timing of oncogene expres 
Sion, as Cre expression results in removal of the stop tran 
Scription signal and, consequently, permits transcription of 
the oncogene. Accordingly, the present invention may be used 
to produce tumors in specific tissues; a Cre gene operably 
linked to a pancreas-specific promoter Such as Pdx1 may be 
used to induce pancreatic cancer in a progeny animal; a Cre 
cDNA operably linked to a colon-specific promoter such as 
Villin may be used to produce a colon cancer in a progeny 
animal, and so forth. In a specific, non-limiting embodiment 
to develop an animal model system for breast cancer (luminal 
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type, ERBB2+ type, and (in particular) basal-like), the second 
transgenic animal may carry a transgene in which a Cre gene 
is operably linked to a milk whey acidic protein (“Wap') 
promoter, so that a selected progeny animal for use as a model 
of breast cancer carries the Eefla 1 cassette and the Wap-Cre 
transgenes. Oncogene expression may be induced in Such an 
animal by lactation. FIG. 1B depicts the targeted Eefla 1 locus 
after Cre-mediated excision of the termination signal. As 
reported in the working example below, where the oncogene 
is an activated Kras gene, a tumor may be produced in as 
short a time as 2 days following parturition. 
The transgenic animal produced according to the invention 
may be any non-human species of animal. In a preferred, 
non-limiting embodiment, the transgenic animal is a mouse. 
In a related set of non-limiting embodiments, the present 
invention provides for a cell line derived from a transgenic 
animal model, as described above, where the cell line is 
produced from a cancerous cell of the transgenic animal 
model in which the oncogene transgene is being expressed. In 
a specific, non-limiting example, the cell line is prepared from 
a mammary tumor of a transgenic mouse expressing activated 
Kras under transcriptional control of the Eefla 1 promoter, 
as described in FIG. 1B. 
In a further related set of non-limiting embodiments, the 
present invention provides for a transgenic animal carrying, 
in addition to Eeflal cassette and promoter/Cretransgenes as 
described above, a heterozygous mutation of IgflR. 
In various non-limiting embodiments, the present inven 
tion provides for use of a transgenic animal model of a human 
tumor, as described above, to identify an agent useful for the 
treatment of said human tumor, where the nature of the tumor 
is determined by the site of expression of the oncogenic 
transgene. In various non-limiting embodiments, the trans 
genic animal model may be a model for breast cancer, or for 
pancreatic cancer, or for colon cancer, or for lung cancer, or 
for skin cancer, or for prostate cancer. In a specific, non 
limiting embodiment, the transgenic animal model is a model 
of basal cell type breast cancer. 
Accordingly, the present invention provides for a method 
comprising (i) providing a transgenic animal, as described 
above, carrying a Eeflal cassette comprising a Cre-activat 
able oncogene and a transgene comprising Cre under the 
control of a promoter permitting conditional activation of Cre 
expression; (ii) providing a condition which results in the 
expression of Cre in the animal with consequent expression of 
the oncogene; (iii) administering, to said animal, a test agent; 
and (iv) determining the effect of the test agent on the growth 
and/or histology of a tumor in the tissue in which the onco 
gene is activated by Cre and expressed, and/or determining 
clinical markers associated with malignancy and/or deter 
mining the survival of the animal, where the ability of the test 
agent to inhibit growth of the tumor, or increase differentia 
tion in the histology of the tumor, or decrease one or more 
clinical marker of malignancy, or increase the Survival of the 
animal, indicates that the test agent may be used to treat the 
human tumor being modeled, and may be advanced to human 
clinical trials. Step (iv) may be achieved by providing a sec 
ond transgenic animal essentially genetically identical to the 
animal of step (i), providing essentially the same condition as 
provided in step (ii), and then determining tumor growth 
and/or histology and/or clinical markers associated with 
malignancy and/or Survival in the second animal, which is not 
administered the test agent and serves as a negative control 
and comparing the results with those obtained with the trans 
genic animal that had received the test agent. Multiple ani 
mals may be administered different dosages of test agent to 
evaluate dose/benefit effect. Clinical markers of malignancy 
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include, but are not limited to, weight of the animal, as well as 
features associated with the tumor resulting from oncogene 
expression (for example, a mammary tumor is readily pal 
pable). In preferred non-limiting embodiments, the test agent 
is a picropodophyllin analogue, Such as, but not limited to, 
those described herein, or another test agent which is an Igflr 
inhibitor. Analogous experiments may be performed using a 
cell line prepared from the transgenic animal expressing the 
oncogene, wherein, after administration of test agent, fea 
tures of the malignant phenotype, including rate of prolifera 
tion, contact inhibition, ability to grow in Softagar, and mark 
ers of apoptosis, may be measured (and where preferably 
these features are compared between cells exposed to the test 
agent and control cells which are not). 
In further non-limiting embodiments, the present invention 
provides for a method of treating a cancer, e.g. a cancer for 
which intact signaling of Igflr is related to tumor develop 
ment and/or Kras is activated, amplified and/or mutated, 
comprising administering, to a Subject in need of such treat 
ment, an effective amount of a picropodophyllin analogue as 
described herein. Igflr-related cancers include, but are not 
limited to breast cancer, prostate cancer, glioblastoma, colon 
cancer, liver cancer, and ovarian cancer. Optionally, said Sub 
ject may further be administered a dose of a second cancer 
therapeutic agent, for example, but not limited to, an epider 
mal growth factor receptor inhibitor such as erlotinib, a Raff 
neoangiogenesis inhibitor Such as Sorafenib, or other agent 
known in the art. 
In still further, non-limiting embodiments, the present 
invention provides for a method of treating basal like breast 
cancer, comprising administering, to a human Subject diag 
nosed as having basal like breast cancer, an effective amount 
of picropodophyllin oran analogue thereof, including, but not 
limited to, a picropodophyllin analogue as set forth herein. 
Optionally, said subject may further be administered a dose of 
a second cancer therapeutic agent, for example, but not lim 
ited to, an epidermal growth factor receptor inhibitor Such as 
erlotinib, a Rafineoangiogenesis inhibitor Such as Sorafenib, 
or other agent known in the art. In specific, non-limiting 
examples, said basal likebreast cancer has a phenotype which 
is estrogen receptor negative, progesterone receptor negative, 
and ERBB2 negative. In further specific, non-limiting 
examples, said basal-like breast cancer has a phenotype 
which includes one or more of the following: epidermal 
growth factor receptor positive, cytokeratin 5 positive, cytok 
eratin 6 positive cytokeratin 14 positive, and/or pG3 positive. 
In specific, non-limiting embodiments of the invention, an 
effective amount of picropodophyllin oran analogue thereof, 
for use in methods of treatment as described above, may be 
between about 30 mg/kg and 80 mg/kg, and may be adjusted 
to optimize effectiveness using standard pharmaceutical tech 
niques. In those specific non-limiting embodiments where 
erlotinib is added, the dose may be, for example and not by 
limitation, between about 25 mg/day and 200 mg/day, or 
between about 50 mg/day and 150 mg/day, for a treatment 
interval between about 1 day and until treatment is deemed 
Successful or adverse effects prevent its continuation. In spe 
cific, non-limiting embodiments, the amount administered 
results in a concentration local to the cancer of between about 
200 nMandabout 800 nM. In specific, non-limiting embodi 
ments, the analogue is compound 18 or compound 21 in an 
amount that, when administered, results in a concentration 
local to the cancer of between about 200 nM and about 800 
nM or about 300-600 nM or about 400-500 nM. 
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Said picrodophyllin and/or analogue thereof may be 
administered by any route known in the art, including but not 
limited to, local application at tumor site or at site of tumor 
excision, intravenous administration, intraarterial adminis 
tration, intraperitoneal administration, intrathecal adminis 
tration, intraventricular administration, intramuscular admin 
istration, Subcutaneous administration, oral administration, 
topical administration, etc. In one specific non-limiting 
embodiment the picropodophyllin analogue is compound 18 
herein. In another specific non-limiting embodiment the 
picropodophyllin analogue is compound 21 herein. 
IGF1RK inhibitors of the invention can be formulated as 
pharmaceuticals using methods well known in the art. Phar 
maceutical formulations of the invention typically comprise 
at least one IGF1RK inhibitor of the invention mixed with 
pharmaceutically acceptable carrier. Preferably the solutions 
are sterile and non-pyrogenic. Compounds of the invention 
can be formulated for parental administration by a variety of 
routes, including by mouth, by injection (e.g., by bolus injec 
tion), or by infusion. 
IGF1RK inhibitors of the invention can be administered to 
patient, either alone or in pharmaceutical compositions where 
they are mixed with suitable carriers or excipient(s) at doses 
to inhibit cancer cell growth as a single agent. IGF1RKinhibi 
tors of the invention may also make cancer cells more Vul 
nerable to treatment with other agents and therefore can be 
used to Supplement standard chemotherapy regimens, such as 
"CHOP therapy (e.g., the use of combination of drugs such 
as Cyclophosphamide, Doxorubicin Hydrochloride. Oncavin 
Vincristine and Prednisone) for a variety of cancers. Related 
members of each family may be substituted for an individual 
component in this combination, and a Subset of these agents 
may also be used. IGF1RK inhibitors of the invention can be 
administered simultaneously or sequentially with a variety of 
chemotherapeutic agents, including but not limited to meth 
otrexate, cis-platin and 5-fluorouracil. 
For example, IGF1RK inhibitors such as picropodophyllin 
analogues of the invention can be used in targeted therapy for 
the following cancers, either alone or in combination with any 
of the following drugs: 
Breast HERCEPTINR) and/or taxol, epothilone, letro 
Zole (e.g., FEMARAR), anastrozole (e.g., ARIMI 
DEX), tamoxifen 
Ovarian taxol 
Prostate bicalutamide (e.g., Casodex) 
Pancreatic gemcitabine 
Non-Hodgkins Lymphoma—RITUXANR) 
Multiple Myeloma—bortezomide (e.g., VELCADER) 
Lung Cancer topotecan (e.g., HYCAMTINR), Etopo 
side, Tarceva (Genentech) 
Testicular—etoposide 
VEPESIDR) 
Skin imiquimod (e.g., Aldara) 
Colorectal—capecitabine (e.g., XELODAR), irinotecan 
e.g., CAMPTOR), Epothilone 
Myeloid Leukemia GLEEVECR) 
The invention will be further described by reference to the 
following examples. These examples should not be construed 
(e.g., ETOPOPHOSR), 
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in any way as limiting the invention to anything less than that 
which is disclosed or which could have been obvious to 
anyone skilled in the art. 
6.EXAMPLE1 
Synthesis 
OMe 
O { O O Br 
Bromoacetyl 1 was synthesized by bromination (Conrad, 
P. C. et al. J. Org. Chem., 1987, 52,586-591) and subsequent 
acetalization of piperonal (Keay, B. etal. Can. J. Chem. 1983, 
61, 1987-1995.) 
OMe 
O { occ OH O 
4-(Dimethoxy)methyl-5-hydroxymethyl(1.2-methyl 
enedioxy)benzene (2) 
(1) 
(2) 
To a solution of bromoacetal 1 (10.0 g, 36.3 mmol) in THF 
(100 mL) at -78°C. was added n-Bulli (25.0 mL, 40.6 mmol. 
1.6 M in hexanes) dropwise via Syringe. The Solution was 
stirred for 1 h at 0°C. and a suspension of paraformaldehyde 
(3.30 g, 36.7 mmol) in THF (60 mL) was added via cannula. 
The reaction was warmed to room temperature, stirred for 2 h, 
and then quenched with HO/EtO. The aqueous layer was 
extracted with EtO, and the combined organics were dried 
(MgSO), filtered, and concentrated. Flash chromatography 
(50% EtOAc/hexanes) gave 2 (6.75 g, 82%). On a larger 
scale, 1 (50 g., 182 mmol) gave 2 in 72% yield (29.7g). H 
NMR. (200 MHz, CD) & 2.47 (t, J=6 Hz, 1H), 2.97 (s, 6H), 
4.50 (d. J=6 Hz, 2H), 5.29 (s. 2H), 5.31 (s, 1H), 6.86 (s, 1H), 
7.27 (s, 1H); 'CNMR. (125MHz, CD) & 52.8, 62.6, 101.6, 
101.8, 108.4, 110.1, 130.4, 1348, 147.5, 148.4; HRMS (EI) 
calculated for CHOs 226.0841, observed 226.0843. Anal. 
Calculated for CHOs: C, 58.39; H, 6.24. Found: C, 58.20; 
H, 6.07. 
O COMe 
KOOO COMe 
(3) 
Dimethyl 1,4-Dihydro-1,4-epoxy-6,7-methylene 
dioxy-2,3-naphthalene-dicarboxylate (3) 
The substrate 2 (23.7g, 105 mmol) was dissolved in excess 
DMAD (251 g, 1.76 mol) and glacial AcOH (23.2 mL, 0.4 
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mol), and the mixture was stirred for 2 h at 80° C. Excess 
DMAD was removed by vacuum distillation, and flash chro 
matography (30% EtOAc/hexanes) gave 3 (56.4g, 90%) as a 
yellow solid. On a smaller scale, 2 (5.53 g, 24.1 mmol) gave 
3 in 92% yield (13.6 g):mp 117-119°C.; H NMR (300 MHz, 
CDC1) & 3.79 (s, 6H), 5.86 (s. 2H), 5.90 (d.J=1 Hz, 1H), 5.95 
(d. J=1 Hz, 1H), 6.95 (s. 2H); 'C NMR (125 MHz, CDC1) & 
53.0, 85.7, 102.2, 105.2, 1414, 146.2, 152.5, 163.5. Anal. 
Calculated for CHO,: C, 59.21; H, 3.98. Found: C, 59.27: 
H, 4.11. 
O COMe { O COMe 
(4) 
Dimethyl meso-(1R,2S*,3R*,4S*)-1,4-Epoxy-6,7- 
methylenedioxy-1,2,3,4-tetrahydro-2.3naphthalene 
dicarboxylate (4) 
IBF Diels-Alder product3 (43.2g, 0.14 mol) was dissolved 
in EtOAc (300 mL), and 10% Pd/C (1.5 g) was added. The 
reaction mixture was hydrogenated at 48 psi for 6 h. The 
reaction mixture was filtered through Celite and concentrated 
to give 4 as a white solid: mp 96-99° C.; H NMR (300 MHz, 
CDC1) & 3.53 (s, 6H), 3.61 (dd, J=2.3 Hz, 2H), 5.41 (dd. 
J=2.3 Hz, 2H), 5.92 (d. J=2 Hz, 1H), 5.96 (d. J=1 Hz, 1H), 
6.82 (s. 2H); 'CNMR (125MHz, CDC1,) & 48.3, 52.3,81.5, 
101.9, 103.9, 137.2, 147.5, 170.5. Anal. Calculated for 
CHO,: C, 58.83; H, 4.61. Found: C, 58.90; H, 4.71. 
O 
{ O OH O 
meso-(1R*,2R*,3S*,4S*)-2,3-Bis(hydroxymethyl)- 
1,4-epoxy-6.7-methylenedioxy-1.2.3,4tetrahy 
dronaphthalene (5) 
(5) 
To a solution of the dimethyl ester 4 (25.0 g, 82 mmol) in 
EtO (500 mL) at 0°C. was carefully added LiAlH4 (6.2g, 
0.16 mol), and the resulting reaction mixture was refluxed for 
1 day. Quenching was carried out by the sequential careful 
addition of HO (6 mL: 30 min stirring), 15% NaOH (6 mL, 
30 min stirring), and H2O (19 mL: 30 min stirring). The 
mixture was neutralized with 1 NHCl solution (100 mL), 
followed by the addition of HO (2.5 L) and extraction with 
EtOAc (6.5 L). The organics were dried (NaSO) and con 
centrated to give 5 as a white solid (16.8 g. 82%); mp 177 
1799 C.; H NMR (500 MHz, CD,OD) & 2.65-2.68 (ddd, 
J=46.9 Hz, 2H), 2.77 (dd, J=9, 10 Hz, 2H), 3.15 (dd, J=6, 10 
Hz, 2H), 5.24 (d. J=4 Hz, 2H), 5.90 (d. J=1 Hz, 1H), 5.94 (d. 
J=1 Hz, 1H), 6.85 (s, 2H); 'C NMR (125 MHz, CDN) & 
44.6, 60.1, 82.4, 101.6, 103.6, 138.2, 146.7. Anal. Calculated 
for CHOs: C, 62.39; H, 5.64. Found: C, 62.26; H, 5.59. 
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O OAc (OOOC 
meso-(1R*,2R*,3S*,4S*)-2,3-Bis(acetoxymethyl)-1, 
4-epoxy-6.7-methylenedioxy-1,2,3,4-tetrahydronaph 
thalene (6) 
(6) 
To a solution of 5 (57.g., 0.23 mol) and DMAP (1.4g, 11.4 
mmol) in pyridine (750 mL) at -10° c. Was added AcO (69.9 
g, 0.68 mol). The mixture was stirred for 16 hat room tem 
perature and EtOAc was added. The organic phase was 
washed with saturated NaHCO solution, 1 N HCl, and 
CuSO (aqueous, Saturated). Drying (MgSO) and concen 
tration provided 6 (7.6 g. 100%); mp 120-122° C.; H NMR 
(300 MHz, CDC1) & 2.05 (s, 6H), 2.82-2.85 (m, 2H), 3.24 
(dd, J=10, 11 Hz, 2H), 3.75 (dd, J–6, 11 Hz, 2H), 5.26 (d. J–4 
Hz, 2H), 5.94 (d. J=1 Hz, 1H), 5.99 (d. J=1 Hz, 1H), 6.76 (s, 
2H); 'C NMR (75 MHz, CDC1) & 21.5, 40.6, 63.1, 82.2, 
102.1, 103.8, 136.7, 147.6, 171.2: Anal. Calculated for 
CHsO,: C, 61.07; H, 5.43. Found: C, 61.20; H, 5.61. 
O { OH 
O OAc 
(1R,2R.3S4S)-2-Acetoxymethyl-1,4-epoxy-3-hy 
droxymethyl-6 7-methylenedioxy-1,2,3,4-tetrahy 
dronaphthalene (7) 
(7) 
A5 LRB flask was charged with PPL (263 g, crude, Sigma) 
and buffer solution (50 mM KPO, pH 7.8, 3.5 L). Diacetate 
6 (20.0 g, 59.8 mmol) in DMSO (380 mL) was added via a 
sidearm while stirring with a mechanical stirrer. The reaction 
was quenched with 4 L of EtOAc after 2.5 hat room tempera 
ture. Following centrifugation to remove insoluble material, 
the organic layer was separated and washed with water. The 
organics were dried over MgSO and concentrated. Flash 
chromatography (50-80% EtOAc/hexane) gave in the follow 
ing order 6 (4.1 g, 21%); 7 11.5 g. 66%; (83% based on 
recovered 6), and diol 5 (0.7g, 5%). The monoacetate 7 was 
determined to be 95% ee by examination of the "H NMR 
spectrum of its derivative Mosher ester: mp 131-134° C.; H 
NMR (360 MHz, CDC1) 81.43-1.58 (br. s. 1H), 2.06(s.3H), 
2.77-2.84 (ddd, J–6, 9, 13 Hz, 2H), 2.87 (dd, J=9, 10 Hz, 1H), 
3.23 (dd, J=10, 11 Hz, 1H), 3.28 (dd, J=6, 10 Hz, 1H), 3.76 
(dd, J–6, 11 Hz, 1H), 5.25 (d. J=4 Hz, 1H), 5.32 (d. J–4 Hz, 
1H), 5.94 (d. J=1 Hz, 1H), 5.98 (d, J-2 Hz, 1H), 6.75 (s, 1H), 
6.83 (s, 1H); 'C NMR (75 MHz, CDC1) & 21.5, 40.3, 43.8, 
61.0, 63.4, 82.3, 82.4, 102.0, 103.7, 103.8, 136.7, 137.2, 
147.3, 147.4, 171.5; C.D=+52.6° (c 0.6, CHCl); HRMS 
(FAB, 3-NBA) calculated for CHO 292.0947 M+), 
observed 292.0952. Anal. Calculated for CHOs: C, 
61.64; H, 5.52. Found: C, 61.72; H, 5.65. 
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O { OTIPS 
O OAc 
(1S,2S,3R.4R)-2-Acetoxymethyl-1,4-epoxy-6,7- 
methylenedioxy-3triisopropylsilyl-oxymethyl-1,2,3, 
4-tetrahydronaphthalene (8) 
(8) 
To a solution of7 (14.5g, 49.6 mmol) and imidazole (7.4g, 
0.11 mol) in DMF (150 mL) at 0°C. was added of TIPSCI 
(11.7 mL, 54.6 mmol) and the mixture was stirred for 7 hat 
room temperature. Et2O was added and the mixture was 
washed with saturated aqueous NaHCO and water. The 
organic phase was dried over MgSO filtered and concen 
trated to give 7 as an oil (22.3g, 100%). H NMR (300 MHz, 
CDC1) 01.03 (d. J=3 Hz, 18H), 1.03-1.22 (m, 3H), 2.06 (s, 
3H), 2.76-2.77 (m, 3H), 3.14 (apt 1, J=10 Hz, 1H), 3.40-3.43 
(m. 1H), 3.78 (dd, J=5, 11 Hz, 1H), 5.24 (d. J–4 Hz, 1H), 5.33 
(d. J=3 Hz, 1H), 5.94 (d. J=1 Hz, 1H), 5.97 (d. J=1 Hz, 1H), 
6.74 (s, 1H), 6.83 (s, 1H); 'C NMR (75 MHz, CDC1) & 12.5, 
18.6, 21.5, 40.2, 44.3, 61.8, 63.3, 82.3, 82.9, 101.8, 103.6, 
104.1, 136.9, 137.5, 147.1, 147.2, 171.3; C.D=+3.00 (c 
0.9, CHCl); HRMS (FAB, 3-NBA, LiI) calculated for 
CHOSiLi 455.2442, observed 455.2443. 
( O OTIPS H 
O 
(1S,2S,3R.4R)-1,4-Epoxy-2-hydroxymethyl-6,7- 
methylenedioxy-3triisopropylsilyl-oxymethyl-1,2,3, 
4-tetrahydronaphthalene (9) 
(9) 
To a solution of acetate 8 (7.1 g, 15.8 mmol) in methanol 
(60 mL) was added KCO (438 mg, 3.17 mmol). The result 
ing Suspension was stirred for 1.5 h at room temperature, 
DoweX 50x8 resin (H' form, 900 mg) was then added, and 
stirring was continued for 30 min. The solution was filtered, 
concentrated and the residue purified by flash chromatogra 
phy (30% EtOAc in hexanes) to yield alcohol 9 (6.43 g, 
100%). "H NMR (300 MHz, CDC1) & 0.98-1.07 (m, 21H), 
2.79-2.85 (m, 2H), 2.97-3.11 (m, 2H), 3.17 (dd, J=5, 11 Hz, 
1H), 3.31 (dd, J–6, 10 Hz, 1H), 5.19 (d. J=4 Hz, 1H), 5.20 (d. 
J=5 Hz, 1H), 5.96 (s.2H), 6.73 (s, 1H), 6.76 (s, 1H); CNMR 
(75 MHz, CDC1) & 12.4, 18.6, 44.4, 44.5, 61.1, 62.1, 82.0, 
82.1, 101.9, 103.3, 103.4, 137.3, 137.6, 147.0, 147.1, IR 
(ATR) 3419 cm-1; O'D=-26.8° (c 1.3, CHCl); HRMS 
(FAB, 3-NBA, LiI) calculated for CHO Si Li 413.2336, 
observed 413.2341. 
O 
{ O OTIPS 
O CHO 
(10) 
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(1S,2R,3R.4R)-1,4-Epoxy-2-formyl-6,7-methylene 
dioxy-3-triisopropylsilyloxy-methyl-1,2,3,4-tetrahy 
dronaphthalene (10) 
To a solution of oxalyl chloride (29 mL of a 2.0 M solution 
in CHCl, 58.1 mmol) at -78°C. was added a solution of 
DMSO (4.86 mL. 32.6 nmol) in CHCl (20 mL) via cannula. 
After 10 min of stirring at -78°C., a solution of 9 (13.9 g, 34.2 
mmol) in CH2Cl (20 mL) was added dropwise via cannula. 
After an additional 30 minat -78°C., a solution of NEt (16.2 
mL, 116 mmol) in CHCl (14 mL) was added. The resulting 
reaction was allowed to warm to -40°C. and kept there for 2 
h. EhO (500 mL) was then added at -40°C., and the reaction 
mixture was allowed to warm to room temperature. The mix 
ture was washed with H2O, aqueous NI LiCl, and brine. The 
organics were dried (MgSO4), filtered, and concentrated to 
give 10 (14.3g, 100%). "H NMR (300 MHz, CDC1) 80.97 
1.20 (m, 21H), 2.99-3.12 (m, 2H), 3.22 (ddd, J=3.5.8 Hz, 1H), 
3.46-3.51 (m. 1H), 5.38 (s, 1H), 5.40 (s, 1H), 5.96 (d. J=1 Hz, 
1H), 5.98 (d. J=1 Hz, 1H), 6.84 (s, 1H), 6.85 (s, 1H), 9.07 (d. 
J=3 Hz, 1H); 'CNMR (125MHz, CDC1) & 12.6, 18.6, 47.3, 
54.2, 62.8, 81.0, 82.7, 102.0, 103.9, 104.0, 136.9, 137.5, 
147.4, 147.5, 202.5: O'D=-26.3° (c 0.8, CHCl); HRMS 
(FAB, 3-NBA, NaI) calculated for CHO, SiNa 427.1917, 
observed 427.1925. 
(11) 
H 
O 
{ CO OTIPS 
O CHO 
(3R,4R)-2-Formyl-4-hydroxy-6,7-(methylenedioxy)- 
3-triisopropylsilyloxymethyl-3,4-dihydronaphtha 
lene (11) 
To a solution of aldehyde 10 (10.5g, 26.0 mmol) in MeOH 
(500 mL) was added NaOMe (1.40 g, 26 mmol) and the 
mixture was heated to reflux for 5 h. HO (245 mL) was then 
added, and CO was bubbled through the solution until the pH 
reached 8 (pH paper). MeOH was removed in vacuo, and the 
resulting aqueous layer was extracted with CH2Cl2. The com 
bined organics were dried (MgSO), filtered, and evaporated 
to provide 11 as a white solid (9.50g,90%): mp 87-89° C.; H 
NMR (500 MHz, CDC1) & 0.93-103 (m, 21H), 1.74 (d. J=5 
HZ, 1H), 3.17 (app t, J=10 Hz, 1H), 3.34 (ddd, J–2, 4, 6 Hz, 
1H), 3.80 (dd, J=4, 10 Hz, 1H), 4.97 (app t, J=HZ, 1H), 6.01 
(s, 1H), 6.02 (s, 1H), 6.83 (s, 1H), 6.93 (s, 1H), 7.24 (s, 1H), 
9.61 (s, 1H); 'CNMR (125MHz, CDC1,) & 12.5, 18.5, 43.4, 
62.7, 70.0, 102.4, 109.8, 110.9, 125.3, 133.8, 136.0, 145.6, 
148.8, 150.7, 1929; IR (ATR) 3395, 1674, 1645 cm; 
O'D+82.0° (c 1.0, CHCl); HRMS (FAB, 3-NBA) calcu 
lated for CHO Si (M+H)" 405.2097, observed 
405.2096. Anal. Calculated for CHO, Si: C, 65.31; H, 
7.97. Found: C, 65.45; H, 7.98. 
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(12) QTES 
( CO OTIPS 
O COOH 
(3R,4R)-6,7-Methylenedioxy-4-triethylsilyloxy-3- 
triisopropylsilyloxymethyl-3,4-dihydronaphthalene 
2-carboxylic acid (12) 
To a solution of aldehyde 11 (900 mg, 2.25 mmol) in DMF 
(20 mL) was added TESCI (715 JtL, 3.38 mmol) and imida 
Zole (460 mg. 6.75 mmol) at 0°C. and the reaction mixture 
was allowed to warm to r.t. overnight. Water was added and 
the product was extracted with Et20, the organic layer dried 
over MgSO and evaporated. The residue was then dissolved 
int-BuOH (40 mL) and 2-methyl-2-butene (12 mL). A solu 
tion of NaClO (1.81 g, 20 mmol) and NaH2PO (1.93 g) in 
water (20 mL) was added and the mixture was stirred over 
night. The product was extracted with EtO, dried over 
MgSO4, concentrated and purified by silica gel column chro 
matography (10-30% EtOAc in hexanes) to give the acid 12 
as a white powder (1.02 g, 85% over 2 steps). H NMR (400 
MHz, CDC1)00.65 (qJ=8.0Hz,6H), 0.94 (t, J=8.0 Hz, 9H), 
1.06 (m, 21H), 3.05, (aptt, J=10 Hz, 1H), 3.34 (ddd, J=10.0, 
4.5, 1.6 Hz, 1H), 3.77 (dd, J=10.0, 4.5 Hz, 1H), 5.03 (s, 1H), 
6.03 (s. 2H), 6.81 (d. J=4.8 Hz, 2H), 7.67 (s, 1H). 
(13) 
QTES 
O 
{ CO OTIPS  
O 
N cy 
O 
(3R,4R)-6,7-Methylenedioxy-2-(N-oxazolidinonyl) 
carbonyl-3-triisopropylsilyloxy-methyl-4-triethylsi 
lyloxy-3,4-dihydronaphthalene (13) 
To a solution of acid 12 (94.0 mg, 1.76 mmol) in THF (20 
mL) at room temperature was added carbonyl diimidazole 
(428 mg, 2.64 mmol). The reaction mixture was stirred over 
night, water was added and the product was extracted with 
Et2O. The organic phase was dried over MgSO and evapo 
rated to provide the crude acyl imidazolide, which was used in 
the next step without further purification. To a deoxygenated 
solution of 2-oxazolidinone (306 mg, 3.52 mmol) in THF (10 
mL) at 78°C. was added n-Bulli (1.65 mL of a 1.6M solution 
in hexanes, 2.64 mmol). After 1 h, a solution of acylimida 
Zolide (1.06 g, 1.76 mmol) in THF (8 mL) was added drop 
wise at -78° C. and the reaction mixture was allowed to stir 
for 5 hat this temperature. The reaction was quenched with 
water and extracted with EtO. The organic layer was dried 
(MgSO), concentrated and the residue purified by column 
chromatography on silica gel (hexanes/EtOAc/EtN, 90:10: 
05 to 70:30:0.5) to yield 13 (650 mg, 62%). "H NMR (400 
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MHz, CDC1).J 0.65 (q, J=8.0Hz, 6H), 0.94 (t, J=8.0 Hz, 9H), 
1.03 (m, 21H), 3.17, (aptt, J=10 Hz, 1H), 3.38 (ddd, J=10.0, 
6.0, 1.6 Hz, 1H), 3.71 (dd, J=10.0, 6.0 Hz, 1H), 4.00 (m, 1H), 
4.16 (apt qJ=9.0Hz, 1H), 4.49 (m, 2H), 4.99 (s.1H), 6.00 (s, 
1H), 6.74 (s, 1H), 6.79 (s, 1H), 7.13 (s, 1H); 'C NMR (100 
MHz, CDC1) & 5.0, 6.8, 11.9, 18.0, 44.1, 45.8, 61.8, 62.1, 
68.5, 76.7, 77.1, 77.4, 1014, 109.2, 110.3, 125.0, 126.3, 
131.4, 137.2, 147.5, 148.8, 153.5, 169.7. 
(14) QTES 
(15) QTES 
O OTIPS 
K N O 
OMe 
(16) 
O T E S 
(17) QTES 
O OTIPS 
{ N O 
Cl MeO OMe 
Typical Procedure for Introduction of E Rings (14-17) 
To a suspension of CuCN (297 mg, 3.30 mmol) in THF (8 
mL) at 5°C. was added 3.3 mL of a solution of the desired 
mono ordi-methoxyphenylmagnesium bromide (1M in THF, 
3.30 mmol). The resulting mixture was stirred for 30 min and 
a solution of Michael acceptor 13 (250 mg, 0.41 mmol) in 
THF (6 mL) was added dropwise at the same temperature. 
After 1.5 h at 5°C., a saturated aqueous solution of NHCl 
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was added and the product was extracted with EtO, the 
organic phase dried over MgSO and evaporated. The product 
was filtered through a short silica gel column (hexanes/ 
EtOAc 80:20) and used directly for the next step. 
Typical Procedure for Desilylative Lactonization 
To a solution of precursor 14-17 (0.21 mmol) in THF was 
added TBAF (1.0 M solution in THF, 4 eq.). The mixture was 
refluxed for 30 minutes and allowed to cool to r.t. A saturated 
solution of NHCl was added and the product was extracted 
with EtO, the organic layer dried over MgSO and evapo 
rated. The crude product was purified by silica gel column 
chromatography (Hexanes/EtOAc, 7:3). 
(18) 
OMe 
4',5'-Didemethoxy-(-)-picropodophyllin (18) 
From Michael acceptor 13 (0.23 mmol. 140 mg) 55 mg of 
18 (68% over 2 steps) were obtained as a white powder. "H 
NMR (400 MHz, DMSO-d6) 02.50 (m, 1H), 3.38 (m hidden 
under water peak, 1H), 3.76 (s.3H), 3.95 (d. J–7.2 Hz, 1H), 
4.36 (dd, J=1004, 604 Hz, 1H), 4040 (dd, J=9.2, 604 Hz, 1H), 
4049 (dd, J=9.2, 1.6 Hz, 1H), 5.92 (s. 2H), 5.94 (s, 1H), 5.97 
(d. J=604 Hz, 1H), 6.84-6.89 (m, 3H), 7.07 (s, 1H), 7.32 (t, 
J=8.2 Hz, 1H); C NMR (100 MHz, DMSO-d6) & 43.2, 
4304, 44.3, 55.5, 67.7, 69.8, 101.2, 105.0, 107.7, 11204, 
11504,121.8, 130. 1, 131.8, 135.3, 145.1, 146.2, 146.2, 159.9, 
17804; HRMS (FAB, 3-NBA) calculated for C.H.O. 
354.1103, observed 354.1100. 
(19) 
OMe 
3',5'-Didemethoxy-(-)-picropodophyllin (19) 
From Michael acceptor 13 (0.23 mmol. 139 mg) 50 mg of 
19 (63% over 2 steps) were obtained as a white powder. "H 
NMR (400 MHz, DMSO-d6) & 2.49 (app. q, J–7.0 Hz, 1H), 
3.29 (dd, J=9.6, 7.8 Hz, 1H), 3.78 (s.3H), 3.92 (d. J=7.8 Hz, 
1H), 4.36 (dd, J=10.0, 6.4 Hz, 1H), 4.39 (dd, J=9.2, 6.4 Hz, 
1H), 4.49 (dd, J=9.2, 1.2 Hz, 1H), 5.91 (s. 2H), 5.92 (s, 1H), 
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5.95 (d. J=6.4 Hz, 1H), 6.96 (d. J=8.8 Hz, 1H), 7.06 (s, 1H), 
7.19 (d. J=8.8 Hz, 1H); C NMR (100 MHz, DMSO-d6) & 
42.6, 43.3, 44.6, 55.5, 67.7, 69.7, 101.2, 104.9, 107.7, 1144, 
130.6, 132.4, 135.2, 135.4, 146.1, 146.1, 158.4, 178.5; 
HRMS (FAB, 3-NBA) calculated for CHO 354.1103, 
observed 354.1113. 
(20) 
OMe 
OMe 
5'-Demethoxy-(-)-picropodophyllin (20) 
From Michael acceptor 13 (0.26 mmol. 160 mg) 40 mg of 
20 (41% over 2 steps) were obtained as a white powder. "H 
NMR (400 MHz, DMSO-d6) & 2.49 (m, 1H), 3.37 (dd, J=9.6, 
8.0 Hz, 1H), 3.73 (s.3H), 3.78 (s.3H), 3.89 (d. J=8.0 Hz, 1H), 
4.35 (dd, J=10.0, 6.4 Hz, 1H), 4.40 (dd, J=8.8, 6.4 Hz, 1H), 
4.50 (d. J=8.8 Hz, 1H), 5.91 (d. J–2.0 Hz, 2H), 5.96 (s, 1H), 
5.97 (d. J=5.6 Hz, 1H), 6.79 (d. J=8.0 Hz, 1H), 6.87 (s, 1H), 
6.96 (d. J=8.0 Hz, 1H), 7.06 (s, 1H); C NMR (100 MHz, 
DMSO-d6) & 43.1, 43.4, 44.3, 55.9, 67.7, 69.7, 101.1, 104.9, 
107.7, 112.2, 113.0, 121.7, 132.4, 135.4, 135.5, 146.1, 146.1, 
148.0, 149.2, 178.5; HRMS (FAB, 3-NBA) calculated for 
CHsO384.1209, observed 384.1213. 
(21) 
O 
OMe MeO 
4'-Demethoxy-(-)-picropodophyllin (21) 
From Michael acceptor 13 (0.25 mmol. 150 mg) 48 mg of 
21 (50% over 2 steps) were obtained as a white powder. H 
NMR (400 MHz, DMSO-d6) & 2.49 (m, 1H), 3.38 (dd, J=9.2, 
8.0 Hz, 1H), 3.74 (s, 6H), 3.91 (d. J–7.2 Hz, 1H), 4.34 (dd. 
J=9.60, 6.4 Hz, 1H), 4.40 (dd, J-9.0, 6.4 Hz, 1H), 4.50 (d. 
J=9.0 Hz, 1H), 5.92 (s. 2H), 5.96 (d. J=6.0 Hz, 1H), 6.00 (s, 
1H), 6.45 (s.3H), 7.06 (s, 1H); C NMR (100 MHz, DMSO 
d6) & 43.1, 43.5, 44.1, 55.6, 67.7, 69.8, 98.8, 101.2, 105.0, 
107.7, 131.6, 135.3, 145.8, 146.2, 1610, 178.4; HRMS 
(FAB, 3NBA) calculated for CHsO 384.1209, observed 
384.1221. 
10 
15 
25 
30 
35 
40 
45 
50 
55 
60 
65 
26 
7. EXAMPLE 2 
In Vitro Testing of Inhibition of Cell Growth 
A murine breast cancer cell line derived from Kras mice 
was used to assay the effect of IGF1RK inhibitors. Approxi 
mately 30,000 cells/well were plated in a 24-well plate which 
corresponds to 20% confluence. The next day (Day 0 for the 
experiment) two of wells were treated with MTT (Thiazol 
Blue Tetrazolium), a substrate used in a colorimetric meta 
bolic assay that reflects cell density. The cells in the rest of the 
wells were treated with DMSO(PPP solvent), PPP or a deriva 
tive of PPP at 500 nM concentration. Forty-eight hours later 
the duplicate wells were assayed. The effectiveness of each of 
the PPP derivatives was compared with that of the original 
PPP 
The five compounds listed in Table 1 were tested. The 
results of the experiments with compounds 3 and 6 are shown 
in Table 2. 
TABLE 1 
Entry Compound 
1 (comparative) 
2 (inventive) 
(-)-picropodophyllin (PPP) 
(-)-picropodophyllin analogue with 3'- 
methoxy substitution on the E-ring (18) 
(-)-picropodophyllin analogue with 4'- 
methoxy substitution on the E-ring (19) 
(-)-picropodophyllin analogue with 3,4'- 
dimethoxy substitution on the E-ring (20) 
3 (inventive) 
4 (inventive) 
5 (inventive (-)-picropodophyllin analogue with 3',5'- 
dimethoxy substitution on the E-ring (21) 
TABLE 2 
Kras Day 2 Day 2 Day 2 Day 2 
cells Day 0 18 21 PPP No drug 
1 0.373 O483 0.505 O.478 O.959 
2 O.362 O.S66 O.464 0.477 O.625 
Average 0.3675 O.S245 O4845 0.4775 O.792 
Compound 18 appeared to be as effective as PPP at inhib 
iting growth of the Kras breast cancer cell line. By varying 
the concentration of compound 18, we obtained a preliminary 
estimate of ~400 nM for ICs value, which very similar to the 
behavior seen with PPP itself on this test cell line. Moreover, 
the 4-methoxy compound (19) shows essentially no activity 
under exactly the same conditions. Such a dramatic SAR 
(Structure Activity Relationship) is quite remarkable. 
8. EXAMPLE 3 
In Vivo Testing 
8.1. Materials and Methods 
Mice 
In addition to the mice conditionally expressing oncogenic 
Kras (for details see EXAMPLE 5, Materials and Methods), 
three mouse strains were used which have been described 
previously; two cre-expressing strains, Hs-cre1 and Wap' 
(Dietrich P. et al., Mamm. Genome (2000), 11:196-205; Lud 
wig T, et al., Oncogene (2001), 20:3937-3948), and 
Igflr' mice (Dietrich P. et al., Mamm. Genome (2000), 
11:196-205). Molecular, histological, microarray and other 
analyses were performed as described in EXAMPLE5. Mate 
rials and Methods and Table 9. 
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Drug Treatments 
Details of the preclinical trial using picropodophyllin Syn 
thesized as described (Buchardt O. et al. J. Pharm. Sci. (1986), 75:1076-1080) and Erlotinib (purchased from Hwa 
sun Biotechnology Co) are described in Results. The drugs 
were dissolved in DMSO and cremophor (9:1) and injected 
intraperitoneally. To calculate tumor volumes, the formula for 
a prolate spheroid (L/6xaxb2 or -axb2/2, where a and b are 
the major and minor axis, respectively) was used. The lengths 
of axes were determined microscopically from sections of 
tumor nodules using a computer assisted morphometry sys 
tem (SpotAdvanced VS. 4.0.1, Nikon Eclipse E400). For 
xenograft experiments, 5x106 MDA-MB-231 cells were 
injected bilaterally into the fat pads of mammary glands 3 and 
4 of female SCID/NOD mice. At ten days post injection, 
when tumors were readily palpable, the mice were randomly 
divided into two groups of five mice each and received the 
same treatment (vehicle or PPP) described above for the 
Kras mice for 3 weeks. For in vitro experiments, MDA-MB 
231 cells were grown in DMEM supplemented with 10% fetal 
bovine serum. Equal numbers of cells were seeded in multiple 
wells of 24-well plates at low density (s.20% confluence at 
day 0) and either DMSO or PPP dissolved in DMSO was 
added to the medium (final concentrations: DMSO 01%, PPP 
500 nM). Cell viability (duplicates) was measured on days 2, 
4 and 6 by using the Thiazolyl Blue Tetrazolium Bromide 
(MTT) colorimetric assay (Mosmann T.J. Immunol. Methods 
(1983), 65:55-63). 
8.2. Results and Discussion 
5 
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Ubiquitous activation of Kras expression by removing the 
floxed block using a cre transgene transcribed in 2-cell stage 
embryos (Dietrich et al., Mammalian Genome (2000), 11: 
196-205) caused embryonic lethality (not shown). On the 
other hand, crosses of Kras' mice with partners expressing 
Cre in particular tissues resulted in tumor development in the 
pancreas, prostate, skin, intestine and the hematopoietic sys 
tem. 
To activate expression of Kras in mammary glands, a 
transgenic line (Ludwig et al. Oncogene (2001), 20, 3937 
48) carrying cre inserted into the Wap locus, encoding a milk 
protein, which is specifically transcribed in alveolar and duc 
tal mammary epithelial cells during late pregnancy and 
throughout lactation (Robinson et al., Development (1995), 
121, 2079-90) was used. Unexpectedly, lactating females 
with an Eef1a1-Kras/Wape genotype (n=28) developed 
palpable multifocal, fully invasive tumors extremely rapidly. 
Specifically, these malignant breast carcinomas appeared 
within a period of 2 days to -2 months after the first delivery 
of pups with a median time of tumor-free survival (Ts) of 
only 9 days (FIG. 1D). This is believed to be the first descrip 
tion of a mouse model in which a malignant neoplasm is 
induced by a single tumorigenic stimulus in one step without 
a requirement for secondary oncogenic events, as evidenced 
by the rapidity of tumor development. This surprising obser 
Vation of apparently single-step tumorigenesis can be attrib 
uted to Kras overexpression at a very high level (23.5+5.8- 
fold higher than that of endogenous Kras mRNA, n=4; see an 
example of Northern analysis in FIG. 1C). However, Western 
Tumor Development in Mice Expressing Oncogenic Kras analysis indicated that the amount of total Kras (including the 
A suitable mouse model has been identified to evaluate mutant protein form) was only moderately elevated in the 
Igflr as a potential therapeutic target in the context of our neoplastic tissue in comparison with the wild-type (~4-fold: 
research program aiming to generate mouse tumors by design FIG. 1C). Whether this is caused by poor translatability O 
using a variant of a genetic scheme involving cre/loXP recom- rapid turnover of the fusion Eefla 1/Kras transcript or some 
bination (Politi K, et al. Oncogene (2004), 23:1558-1565). other posttranscriptional mechanism remains unclear. 
Depending on the tissue-specificity of the promoter driving Histopathological Analysis of Kras-induced Mammary Car 
cre expression, tumors develop at chosen anatomical sites of cinomas (see FIG. 2) 
progeny derived by mating Cre-producers with mice carrying 
a dormant oncogenic transgene that becomes functional after Female mice developing tumors Were sacrificed when 
excision of a floxed DNA segment blocking its expression. 40 moribund within a period of 9 days to -3 months (this brief 
For development of a targeting cassette for high-level time of observation only rarely permitted the detection of 
expression of any chosen cINA introduced into a defined lung metastases). In all examined cases (n=37), the Kras 
genomic site by knock-in, the Eeflal locus (encoding a trans- induced carcinomas involved most or all mammary glands 
lation elongation factor) was used as a recipient site for trans- and were either multifocal or consisted of large masses gen 
genic knock-in of various sequences, including a constitu- 4s erated by coalescence of Smaller components. The tumors 
tively active oncogenic Kras cDNA Kras 4B(G12D); Kras. were histologically heterogeneous and four coexistent types 
Eefla1 is strongly transcribed (Soares et al., Proc. Natl. Acad. of invasive carcinomas were identified at variable propor 
Sci. U.S.A. (1994), 9,9228-32) and yields an abundant protein tions: adenocarcinomas (Dunn Type A/B tumors), and pale, 
product (-2% of the total cell protein: Codeelis, Trends Bio- squamous and spindle cell (sarcomatous) carcinomas PCC, 
chem. Sri (1995), 20, 169-70). In the Eefla targeting cas. SCC and SRF, their of cancer forms are 
sette (FIGS. 1A and 1B) which was used here, 5' and 3 summarized in EXAMPLE 5, Table 3. 
regions of Eeflal gene homology are flanking a segment, Overall, however, the slow-growing adenocarcinomas, 
eventually targeted into the first intron of the locus, which which exhibited a very low proliferation index (-10-20% of 
consists of a splice acceptor site, a floxed selectable marker the corresponding value for any other component), were on 
associated with a “stop” sequence and a cDNA, for example average the smallest tumor constituent (14% of the total 
Kras, inserted into chosen restriction sites of a polylinker. tumor mass; ~40-50% of the size of any other form; Table 3). 
TABLE 3 
Histopathological Analysis of Mammary Carcinomas 
Adenocarcinoma (Dunn AB) Pale Cell Carcinoma Squamous Cell Carcinoma Spindle Cell Carcinoma 
A. Kras Tumors 
Component size (%) 14.0 + 2.2 (n = 37) 
Proliferation index 4.4 + 0.6 (n = 10) 
(%) 
24.7 + 5.1 (n = 37) 
46.7 + 2.3 (n = 10) 
37.2 + 4.7 (n = 37) 
22.1 + 1.5 (n = 8) 
24.7 + 4.5 (n = 37) 
23.0 + 5.6 (n = 6) 
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TABLE 3-continued 
Histopathological Analysis of Mammary Carcinomas 
Adenocarcinoma (Dunn AB) Pale Cell Carcinoma 
Well-differentiated microacinar 
structures resembling budding 
alveoli and consisting of Small, 
uniform-size cells with Small, 
round, hyperchromatic nuclei 
(Dunn TypeA). Occasionally, 
Solid cords, nests or trabeculae 
without glandular differentiation 
are detected (Dunn B). 
Morphology 
nuclei. 
Solid nests of large pleomorphic 
cells with some (usually Small) 
degree of keratinization, which 
possess lightly staining (pale') 
cytoplasm and nuclei. The pale 
cells are sometimes associated 
with small basophilic cells with 
scant cytoplasm and ovoid 
Squamous Cell Carcinoma Spindle Cell Carcinoma 
Irregular nests of flattened 
eosinophilic cells of variable 
size that exhibit distinct cell 
borders and clear evidence of 
keratinization (squamous 
metaplasia). These nests are 
commonly separated by broad 
bands of tumor stroma and 
Surrounded by inflammatory 
infiltrate. 
Fascicles of spindle-shaped 
cells with elongated large 
nuclei exhibiting infiltrative 
growth (there are no defined 
borders with the adjacent 
non-neoplastic tissue; 
sarcomatous metaplasia). 
B. Kras' Tumors After Conditional Ablation of Igflr 
Component size (%). 43.4+ 5.5 (n = 9) 
Proliferation index 3.8 + 0.4 (n = 9) 
(%) 
15.9 + 6.9 (n = 9) 
49.4 + 3.0 (n = 8) 
It was observed that this form of carcinoma was histologically indistinguishable from a rare tumor 
19.4 + 8.3 (n = 9) 
18.4 + 6.4 (n = 3) 
21.4 + 6.6 (n = 9) 
24.0 + 2.9 (n = 4) 
type that appears specifically in the GR mouse strain carrying an active endogenous 
MMTV provirus (Mtv2) on chromosome 18 (van Nie R and Dux A.J. Nati. Cancer inst. (1971), 46:885-897; Strum JM Am. J. Pathoi. (1981) 103: 283-291), but differed in immunophenotype (not shown), 
The Dunn adenocarcinomas were well-differentiated 
microacinar structures (Dunn Type A) or occasionally solid 
nests without glandular differentiation (Dunn Type B) and 
corresponded morphologically to tumor types induced by the 
mouse mammary tumor virus (MMTV; Hoeber-Harper, New 
York), (1959) pp. 38–84; Sass B and Dunn TB, JNatl Cancer 
Inst (1979); 62:1287-1293). On average, they were the small 
est and slowest-growing tumor constituents (Table 3). The 
PCC, which consisted of large, lightly-staining (“pale') cells, 
were also adenocarcinomas, but exhibited in some areas signs 
of keratinization. Morphologically, they are indistinguishable 
from a rare tumor type that appears specifically in the GR 
strain of mice carrying an active endogenous MMTV provi 
rus (Mtv2) on chromosome 18. However, immunophenotypic 
differences between the Kras- and MMTV-induced PCC 
were identified. Clear evidence of keratinization (squamous 
metaplasia) was seen in SCC, whereas the spindle-cell tumors 
exhibited sarcomatous metaplasia. The microacinar (Dunn 
A), pale and squamous cell tumors were correlated with the 
presence of corresponding forms of carcinoma in situ (CIS: 
also referred to in mice as “mammary intraepithelial neo 
plasm', MIN; Cardiff R D et al., The Mouse in Biomedical 
Research. Volume II. Diseases, Second ed., eds. Fox J Get al., 
(Elsevier, New York), (2007), pp. 581-622; FIG. 2A, insets). 
Because the squamous CIS was rarely observed, we surmise 
that it gives rise to invasive SCC very rapidly. A distinct 
spindle-cell CIS was not found, but occasionally squamous 
CIS exhibiting foci of sarcomatous metaplasia could be rec 
ognized. 
One type of carcinoma in situ (Small-cell, low nuclear 
grade CIS) exhibited a pattern similar to that of lobular neo 
plasia in human CIS. It was composed of Small cells filling 
lobules, but never extralobular ducts, and could be discrimi 
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nated from the cytologically and immunophenotypically 
identical invasive microacinar carcinoma Solely on the basis 
of preservation of a myoepithelial layer. A second CIS type, 
also retaining a discontinuous layer of myoepithelial (p63 
positive) cells, formed multiple cellular layers in ducts, and 
was also present in lobuloalveolar units, where it filled alveo 
lar spaces in the form of Solid nests or nodules. This high 
grade CIS was found either in isolation or adjacent to an 
invasive component and consisted of large cells indistin 
guishable in appearance and immunostaining characteristics 
from those seen in PCC. Interestingly, in several independent 
cases, conglomerates of large ductal CIS cells were observed 
budding from a Suprabasal location outward to acquire a 
position between the (still intact) luminal epithelial layer and 
the overlying myoepithelial layer (at least in the human mam 
mary epithelium, multilineage progenitor cells are thought to 
reside in a suprabasal position). A third type of CIS was 
composed of squamous cells and was the only one exhibiting 
foci of sarcomatous metaplasia. Apparently, this CIS was 
giving rise to invasive squamous cell carcinoma quite early, as 
it was observed less frequently than the other forms. 
To assess the origin, relationships and signaling character 
istics of the carcinomas by immunophenotyping, an extensive 
panel of markers was used (FIG. 2A, Table 4 and FIG. 6). The 
results indicated that the ER"/PR" Dunn adenocarcinomas, 
which express exclusively luminal cell markers, such as 
cytokeratin 18 (CK18; Krt18), are luminal-type cancers pre 
sumably derived from differentiated luminal epithelial cells. 
In contrast, on the basis of their distinct features, the pale, 
squamous and sarcomatous carcinomas appear to correspond 
to basal-like breast carcinomas. 
TABLE 4 
Immunophenotyping Data 
Normal CIS Carcinoma 
V P L I PI Small Cell Large Cell Sq. Cell Dunn A/B PCC SCC SRC 
Luminal markers 
Ck18 (Krt18) ------ ------ ------ ------ ------ ------ ---- -- ------ ---- ---- ---- 
ER ND ND IND IND ND ---- -- ---- 
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Immunophenotyping Data 
Normal CIS Carcinoma 
V P L I PI Small Cell Large Cell Sq. Cell Dunn A/B PCC SCC SRC 
PR ND IND IND IND IND ---- +f- ---- 
GATA3 ------ ------ ------ ------ ------ ------ ---- ------ ---- 
Basal markers 
Ck5 (KrtS) ------ ------ ------ ------ ------ +f- ------ --- ------ ---- 
Ck14 (Krt14) ------ ------ ------ ------ ------ ---- ------ --- ------ ------ 
SMA (Actg.2) ------ ------ ------ ------ ------ +f- +f- 
p63 (Trp63) ------ ------ ------ ------ ------ -- ------ -- ------ 
“Stem Cell markers 
Itga.6 ---- +f- +f- +f- ---- +f- ---- +f- ---- 
Itgb1 ND IND IND IND ------ ND ND ND ---- ------ ------ ---- 
CD24 ND IND IND IND -- ND ND ND ---- -- -- +f- 
Ck6 (Krtó) ---- +f- +f- +f- ---- ---- ------ ++ +++ +f- 
Nestin +f- +f- +f- ------ -- ------ -- ---- 
Annexin VIII +f- +f- ---- +f- ------ +++ +++ +f- 
Sca1 +f- +f- +f- +f- ---- --- ------ 
Signaling markers 
bErk +f- ---- ---- ------ ---- ---- ------ ------ ------ 
pAkt1 -- ---- -- +f- ------ ------ ------ ---- ---- 
S6 -- ------ ---- +f- ------ ------ ------ ------ -- 
gflr +f- -- -- +f- ---- ------ ---- ---- ------ ---- +f- 
gf1 +f- -- 
gf2 
Egfr ---- -- -- -- ---- -- ------ ------ -- --- ------ 
Erbb2 (Neu) -- -- +f- -- -- -- -- -- -- ---- -- 
Erbb3 -- ------ ------ -- --- ------ ------ 
Notch 1 ---- ++ +++ +++ +f- -- ------ ---- -- ------ ---- -- 
agged ------ ------ ------ ------ ------ 
Myc --- ------ ---- -- ------ ---- ------ - - ------ 
Fos 1 -- -- -- -- ------ +f- +++ +++ 
Other markers 
E-cadherin ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ 
Vimentin -- +f- -- ------ 
B-catenin (nuclear) ----- 
B-catenin (cell Surface) +++ +++ +++ +++ +++ ------ ------ ------ ------ --- ------ 
The intensity of marker immunostaining signal (-: absent; +: weak in >15% of the cells; ++: focally strong; +++: generally strong) is compared between 
wild-type mammary glands of virgin (V), pregnant(P), lactating (L), involuting (I) and postinvolutional (PI) female mice and in situ or invasive carcinomas, 
The results indicated that the cancer forms induced by 
Kras could be classified into two groups differing in the 
cell-of-origin. Whereas expression of exclusively luminal 
epithelial cell markers (such as keratin 18; Krt18) was 
detected in small-cell CIS and Dunn A/Badenocarcinomas, 
the large-cell CIS and the pale, squamous and sarcomatous 
carcinomas exhibited positive immunostaining both for lumi 
nal markers (Krt18) and for basal cell markers (Krt5, Krt14. 
p63), and also for presumptive stem cell markers. Apparently, 
the Dunn adenocarcinomas, which are also hormone recep 
tor-positive (ER"/PR), are luminal-type neoplasms, presum 
ably derived from differentiated luminal epithelial cells, 
whereas the ER/PR pale, squamous and sarcomatous 
tumors are basal-like cancers derived from undifferentiated, 
bipotential precursor cells and not from myoepithelial cells, 
as they do not co-express p63 and Smooth muscle actin 
(SMA), which are the functional markers of myoepithelial 
differentiation. This interpretation is also strongly supported 
by expression profiling data. 
On the other hand, a potential relationship between the 
three basal forms is not a straightforward issue. For example, 
it was considered that the PCC and the metaplastic and more 
extensively keratinized squamous cell carcinomas (SCC), 
which are often found intimately interspersed, might be 
related and could represent two extreme forms of a spectrum 
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of adenosquamous carcinomas. However, it may be more 
likely that these two tumor forms originate from different cell 
precursors, as suggested from the identification of distinct 
CISS and the results of immunophenotyping. In regard to the 
spindle-cell (sarcomatous) carcinomas (SRC), it is important 
to note that they have lost the epithelial marker E-cadherin, 
which is present in PCC and SCC, but strongly express 
Vimentin, a mesenchymal cell marker. Nevertheless, as in 
other cases of histopathologically heterogeneous mammary 
tumors, the SRC presumably are epithelial and not mesen 
chymal tumors that could be derived from an adenosquamous 
component by EMT (epithelial-mesenchymal transition). 
The term “precursor cell' is used herein to refer to the 
cell-of-origin of the basal-like carcinomas that have been 
identified in these experiments. It is notable that the PCC 
expresses Gata3, a luminal cell marker for mature mammary 
epithelium, which is absent from SCC. This difference may 
by indicative of distinct cells of origin, but it cannot be inter 
preted as suggesting that PCC could be derived from termi 
nally differentiated luminal cells, as Gata3 is expressed in 
precursor cells of mammary primordia. Differences in the 
expression of particular markers, such as CK5/14 and p63, 
also exist between SRC and the other two basal-like compo 
nents (PCC and SCC). Nevertheless, the overall similarities 
between the three basal forms, including the expression of 
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putative stem cell markers and particular signaling compo 
nents validated by molecular data, permit a clear-cut demar 
cation from the luminal Dunn adenocarcinomas. 
“Stem cell markers' should not be confused with “markers 
of stemness', i.e. cellular constituents that bestow stem cell 
behavior (self-renewal capacity and potential to generate dif 
ferentiated derivatives) and/or are uniquely expressed in stem 
cells. In fact, with the apparent exception of the Lgrš gene, 
markers of sternness are generally unavailable. Instead, “stem 
cell markers' correspond to an “expression signature' (i.e. a 
combinatorial, rather than exclusive expression of some set of 
cellular elements) capable of discriminating a cell population 
enriched in operationally defined stem cells. Analysis of the 
distribution of the CD29 (integrin B1; Itgb1) and CD49f(inte 
grin C.6. Itga6) by using double immunofluorescence showed 
that both of these markers were co-localized in the basement 
membrane of the myoepithelial layer while, in addition, Itgb1 
was present in the basolateral, but not the luminal aspect of 
luminal cells. This distribution was maintained in microaci 
nar adenocarcinomas, but only for Itgb1, whereas the basal 
like forms had altered patterns. Thus, all SCC cells exhibited 
intense labeling for both markers co-localized circumferen 
tially, while the intensity of signal in PCC and SRC was 
variable and did not involve all cells. An additional marker 
that was examined was Scal, which was found to be present 
in PCC and SCC, but not in SRC or Dunn tumors. 
Of the three major molecularly classified subtypes of 
human breast cancer (Perou C M. et al. Nature (2000), 406: 
747-752: Sorlie T, et al. Proc Natl Acad Sci USA (2001), 
98:10869-10874: Sorlie T, et al. Proc Natl Acad Sci USA 
(2003), 100:8418-8423), luminal cancers are estrogen recep 
tor-positive (ER), whereas the other two classes are ER 
negative and either overexpress ERBB2 (ERBB2") or exhibit 
phenotypic features of basal/myoepithelial cells (basal-like 
cancers). The latter also lack progesterone receptor (PR) and 
ERBB2 (“triple negative breast cancers'; see Da Silva L., et 
al., J. Clin. Pathol. (2007), 60: 1328-1332: Reis-Filho J S and 
Tutt AN. Histopathology (2008), 52:108-118), but frequently 
express EGFR and basal markers, such as cytokeratins (CK) 
5/6 and/or 14 and p63 (NielsenTO, et al., Clin. Cancer Res. 
(2004), 10:5367-5374.). The basal-like group (15-20% of all 
breast cancers), which is quite heterogeneous, includes high 
proportions of BRCA1-associated and also medullary and 
metaplastic (squamous, spindlecell and other) Subtypes. 
Interestingly, KRAS amplification was detected in 56% (/16) 
of examined basallike human breast cancers (HerschkowitzJ. 
et al., Genome Biol. (2007), 8:R76). 
On the basis of their distinct features, the Krasi-induced 
ER/PR pale, squamous and sarcomatous mouse carcino 
mas, which are immunopositive for both luminal (CK18) and 
basal cell markers (CK5, CK14, p.63, and rarely smooth 
muscle actin), and also for presumptive stem-cell markers 
(Table 4), are analogous to some of the forms of human 
basal-like cancers. It is likely that these basal-like murine 
tumors are derived from undifferentiated, bipotential precur 
sor cells and not from myoepithelial cells (this hypothesis 
concerning "cells-of-origin' is discussed in detail in 
EXAMPLE 5). Consistent with this view is the fact that the 
Kras activating cre is embedded in the Wap locus that is not 
expressed in fully differentiated myopithelial cells. 
A morphological similarity between mouse pale cell car 
cinoma and a type of human basal-like breast cancer that was 
also correlated with KRAS copy gain, was observed. In a 
collection of human breast cancer specimens (n=94), 17 
samples (18%) were found to be basal-like (triple-negative 
and positive for CK5/6), while 77 (82%) were non-basal (R. 
Parsons and H. H., unpublished). Analysis of the 17 basal 
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cancers for amplification of the KRAS locus by using CGH 
showed that 5 of the specimens scored positive, while further 
analysis of a subset by using FISH identified a sixth positive 
sample. The corresponding KRAS amplification frequency in 
the non-basal samples detected by CGH was 3/77 (-5% vs. 
-35%, 6/17: P=0.002, Fisher's exact test). Three of the basal like specimens with amplified KRAS displayed medullary 
features (large tumor nodules with pushing, rather than infil 
trative borders, composed of large cells with irregular, some 
times bizarre nuclei growing in a syncytial fashion) but none 
of them met all of the criteria for classical medullary carci 
noma classification (they are referred to here as "atypical 
medullary breast cancer, AMBC; Fadare O and Tavassoli F 
A. Adv. Anat. Pathol. (2007), 14:358-373). Interestingly, two 
of these AMBCs, contained abundant large cells with pale or 
clear cytoplasm and exhibited a strong resemblance to the 
histomorphological signature of the PCC observed in our 
mouse model. To validate this correlation, an available set of 
triple-negative AMBCs (n=8) was examined and it was 
observed that most of them (7/s) were at least focally compa 
rable to the PCC in Kras mice (FIG. 2B). Immuno-his 
tochemical analysis showed that all 8 of these AMBCs were 
positive for basal cytokeratins 5 and 14 and showed IGF1R 
staining along their cellular surface (FIG. 2B). FISH analysis 
was performed to assess potential amplification of the KRAS 
locus and found that 3 of these cancers, all of which possessed 
as a major component large pale cells, tested positive (FIG. 
2C; P=0.015; using the data% for basal and 777 for non-basal 
specimens). Therefore, the results showed that a subset of 
basal-like human breast cancers preferentially exhibit ampli 
fication of the KRASlocus frequently associated with a pale 
cell carcinoma character. 
Molecular Analysis of Kras-induced Mammary Carcinomas 
To complement the morphological information described 
above, the expression profiles of normal postinvolutional 
mammary glands (n=5) and Kras-induced carcinomas 
(n=14) were examined by microarray analysis, and it was 
found that they were readily discriminated by unsupervised 
hierarchical clustering (FIG. 7). Although the dendrogram 
also stratified the tumors according to the predominating 
basal-like component, only average differential expression 
levels in tumors vs. normal glands was compared to simplify 
the analysis (the microarray data were validated in part by 
immunohistochemistry and Northern or Western blotting). 
Comparisons of the profiling results with lists of basal and 
luminal markers chosen for classification of human breast 
cancers (Sorlie et al., BMC Genomics (2006), 7:127; Hersch 
kowitz et al., Genome Biol. (2007), 8, R76) and also with 
datasets of upregulated and downregulated genes in basal and 
non-basal breast cancers (Farmer et al., Oncogene (2005), 24. 
4660-71; Richardson et al., Cancer Cell (2006), 9, 121-32) 
showed unequivocally that the Kras-induced tumors are 
basal-like carcinomas, in agreement with the histological evi 
dence. In fact, the null hypothesis that there is no statistical 
difference in the representation of basal and luminal markers 
in the groups of upregulated and downregulated genes in 
Kras tumors was overwhelmingly rejected (Table 5). In 
addition, consistent with the hypothesis that the basal-like 
Kras cancers evolve from precursor cells of the mammary 
epithelium, the data showed that the pattern of overexpressed 
genes in the tumors resembled much more the profile of a 
mammary cell population enriched in stem cells than that of 
another population consisting predominantly of luminal cells 
(Stinglet al., Nature (2006), 439, 993-97; high statistical 
significance: Table 5). Not unexpectedly, there was a high 
degree of similarity between the profiles of Kras-induced 
mouse lung (Sweet-Cordero et al., Nature Genet. (2005), 37. 
48-55) and mammary tumors (Table 5). Finally, comparisons 
of the microarray results with those for other mouse mam 
mary tumors supported strongly the view that Kras deregu 
lates to a much larger extent all major signaling pathways 
(Tables 6-8). 
US 8,859,614 B2 
35 36 
TABLE 5 
Expression profiling data 
Markers in the Profile of Krasi-induced Mammary 
Cancers Represented in the Comparison Datasets 
Upregulated (3154 total Downregulated (2092 total 
Markers in Markers in 
Markers Common Common 
Comparison Datasets (D) (total #) (#) % P (#) % P 
Human Breast Cancer 
D1a: Basal Markers 317 101 31.9 <1O-6 37 11.7 O.O1 
D1b: Luminal Markers 263 38 14.4 47 17.9 
D2a: Basal Markers 150 41 27.3 OOO2 15 1O.O O.O2 
D2b: Luminal Markers 105 13 12.4 2O 19.0 
D3a: Upregulated in Basal-like Cancers 1341 453 33.8 <1O-5 154 11.5 2 x 10 
D3b: Downregulated in Basal-like Cancers 1520 327 21.5 263 17.3 
D4a: Upregulated in Basal-like Cancers 1.191 362 30.4 OOO7 131 11.O 10-4 
D4b: Downregulated in Basal-like Cancers 858 229 26.7 140 16.3 
Mouse Mammary Cells 
D5a: “Stem Cell Markers 243 119 49.0 3 x 10 35 14.4 O.O15 
D5b: Luminal Markers 222 64 28.8 47 21.2 
Kras-Dependent Expression 
D6a: Upregulated in Mouse Lung Cancer 487 183 37.6 <1O-6 S4 11.1 <106 
D6b: Downregulated in Mouse Lung 439 92 21.0 164 37.4 
Cancer 
Markers of the indicated datasets D1-D6 (filtered as described in EXAMPLE 5 Methods) are from Sorlie T, et al. BMC Genomics (2006) 7: 
27; Herschkowitz J., et al. Genome Bioi (2007), 8: R76; Farmer Petal. Oncogene (2005), 24:4660-4671; Richardson AL, et al. Cancer Ceil 
(2006), 9:121-132; Stingl J, et al. Nature (2006), 439:993-997; Sweet-Cordero A, et al. Nat Genet (2005), 37:48-55. For sets D3 and D4, we 
used the meta-analysis data of the Oncomine database (www.oncomine.org), 
TABLE 6 
Expression of signaling pathway components in mouse mammary tumors 
i 
1 3 
3 
3 
1 
8 
2 
4 
2 
O 
1 
25 
1 
1 
DMBA 
% P 
9.3 O.OO2 
4.8 OOOO2 
15.8 O.O2 
S.O. O.OOO6 
10.8 OOO1 
S4 O.OOO8 
8.3 O.OOO3 
2.2 6 x 10 
O.OO)4 
1O.O NS 
3O.S. O.OOO8 
1.8 2 x 10 
2.6 6 x 10 
Kras Neu Mye Tag 
Pathway # Total. A # % # Total B # % P i % P i % P 
Mapk 162 3S 21.6 140 14 10.0 O.OO3 8 5.7 4 x 10 13 9.3 O.O2 
Pi3k 66 19 28.8 62 9 14.5 O.O2S 4 6.5 7 x 10 3 4.8 OOOO2 
mTOR 2O 1O SO.O 19 2 10.5 O.OO8 6 31.6 NS 1 5.3 O.OO2 
Erbb 25 13 S2.0 2O 3 15.O O.OO9 O O 7 x 10 1 S.O. O.OOO6 
Wn 85 26 30.6 74 1 14 s-10 3 4.1 6 x 10 7 9.S. O.OOO6 
Notch 42 15 35.7 37 1 2.7 O.OOO2 3 8.1 O.OO3 2 S4 OOOO8 
Tgfb 61 23 37.7 48 4 8.3 O.OOO2 2 4.2 2 x 10 4 8.3 O.OOO3 
Jaki Stat 111 22, 19.8 89 6 6.7 O.OO45 2 2.2 6 x 10 4 4.5 O.OOO8 
Hedgehog 19 7 36.8 19 O O O.OO)4 1 5.3 O.O2 O O O.004 
Vegf 10 4 40.O 10 1 100 NS O O O.04 2 2O.O NS 
Cell Cycle 88 48 S4.5 82 19 23.2 2 x 10 32 39.0 O.O2 41 SO.O NS 
Apoptosis 61 18 29.5 56 5 8.9 O.OO3S 4 7.1 O.OO1 4 7.1 O.OO1 
>1 Pathway 43 16 37.2 39 4 10.3 O.OO3S 3 7.7 O.OO1 5 12.8 OOO8 
“Only upregulated genes are considered (see Table 9 for a list of genes encoding signaling components that are upregulated in carcinomas induced by Kras). The total number (ii) of unique 
components in each major signaling pathway (listed in Table 8) is shown in columnA, except for the lastrow (components participating in more than one pathway), The number ofapathway 
components that are overexpressed in Kras-induced cancers are compared with the corresponding numbers reported (Herschkowitz, J.I. etal. Genome Bioi (2007), 8: R76) for two luminal 
type mammary tumors induced by Neu (Erbb2) or Myc, a basal-like cancer induced by DMBA administration and a tumor with mixed basal and mesenchymal characteristics induced by 
Tag (SV40 large Tantigen). For the reported cases, the total number of components (columnB) is less than that in column A (the missing entries are not represented in the Affymetrix 430 
2.0 chip that we have used). The percentages of overexpressed, pathwayspecific genes are higher in the Kras' than in the other tumors, Statistical analysis (Fisher's exact test) comparing 
the expressed and nonexpressed components in Kras' tumors with the corresponding data of each of the other cases shows that there are highly significant differences (columnsP) with 
very few exceptions (NS). Analogous differences were not observed for downregulated genes. 
TABLE 7 
Components of signaling pathways overexpressed in Kras'-induced carcinomas 
SYMBOL NAME CN 
Rac/MAPK Pathway 
Arrb2 arrestin beta 2 2.8 2.8 
Atf2 activating transcription factor 2 2.7 
Atfa. activating transcription factor 4 2 2.5 
Braf Braftransforming gene 3.1 
Dusp14 dual specificity phosphatase 14 10.2 3.7 
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Components of signaling pathways overexpressed in Kras'-induced carcinomas 
SYMBOL NAME CN 
Dusp15 Dual specificity phosphatase 15 2.6 
Dusps dual specificity phosphatase 5 3.5 
Dusp6 dual specificity phosphatase 6 6 
Dusp7 dual specificity phosphatase 7 13.8 
Dusp9 dual specificity phosphatase 9 7.7 
Flna filamin, alpha 2.7 
Flimb filamin, beta 9.2 
Gna12 guanine nucleotide binding protein, alpha 12 7 2.8 
Hras1 Harvey rat Sarcoma virus oncogene 1 3 
Map2k3 mitogen activated protein kinase kinase 3 2.1 
Map2k4 Mitogen activated protein kinase kinase 4 2.5 
Map3k1 mitogen activated protein kinase kinase kinase 1 2 
Map3k7 mitogen activated protein kinase kinase kinase 7 2.7 
Map3k7ip2 mitogen-activated protein kinase kinase kinase 7 interacting protein 2 2.5 
Map4k4 mitogen-activated protein kinase kinase kinase kinase 4 2.9 
Mapk13 mitogen activated protein kinase 13 3.1 
Mapk14 mitogen activated protein kinase 14 2.7 
Mapk9ip2 mitogen-activated protein kinase 9 interacting protein 2 2.4 
Mapk8ip3 mitogen-activated protein kinase 8 interacting protein 3 3.1 
Mapkapk2 MAP kinase-activated protein kinase 2 3 
Nras neuroblastomaras oncogene 3.7 
Pak1 p21 (CDKN1A)-activated kinase 1 3.3 
Pdgfa platelet derived growth factor, alpha 2.5 2 
Pdgfrb platelet derived growth factor receptor, beta polypeptide 2.5 
Ppm1b Protein phosphatase 1B, magnesium dependent, beta isoform 2.2 2.5 
Ppp5c protein phosphatase 5, catalytic Subunit 3.3 
Rasa1 RAS p21 protein activator 1 3.1 
Rras2 related RAS viral (r-ras) oncogene homolog 2 2.5 
Stmin1 stathmin 1 3.4 2.4 
Taok1 TAOkinase 1 5.4 
Phosphatidylinositol Pathway 
Akt1 thymoma viral proto-oncogene 1 19 
Akt3 thymoma viral proto-oncogene 3 2.5 2.2 
Calm3 calmodulin 3 2.5 
Calm4 calmodulin 4 2.9 2.3 
Calml3 calmodulin-like 3 34.2 
DgkZ diacylglycerol kinase Zeta 2.4 
inpp11 inositol polyphosphate phosphatase-like 1 4.2 
itpr1 inositol 14,5-triphosphate receptor 1 2 
itpris inositol 1,4,5-triphosphate receptor 3 6.7 
Ocrl oculocerebrorenal Saydrome of Lowe 2.5 
Pik3cg phosphoinositide-3-kinase, catalytic, gamma polypeptide 2.2 S 
Pik3r3 phosphatidylinositol 3 kinase regulatory Subunit, polypeptide 3 (p55) 2.3 
Pip5k1a. phosphatidylinositol-4-phosphate-5-kinase, type 1 alpha 2.9 
Pip5klb Phosphatidylinositol-4-phosphate-5-kinase, type 1 beta 2.4 
Pip5k2a phosphatidylinositol-4-phosphate-5-kinase, type II alpha 2 2.1 
Plp5k2c phosphatidylinostiol-4-phosphate 5-kinase, type III, gamma 5.8 
PC3 phospholipase C, delta 3 3.3 
Syni 1 Synapiolanin 1 2.4 
Synij2 synapiolanin 2 3.2 
mTOR Pathway 
DditA DNA-damage-inducible transcript 4 10.2 
Eifa-E eukaryotic traslation initiation factor 4E 2.9 
Eifa-e2 eukaryotic translation initiation factor 4E member 2 2.7 
Frap1 FK5D5 binding protein 12-rapamycin associated protein 1 2.4 
Hf1a hypoxia inducible factor 1, alpha subunit 2.4 
Rpséka1 ribosomal protein B6 kinase polypeptide 1 2.1 3.5 
Rpsékað ribosomal protein B6 kinase polypeptide 6 7 6.4 
Rpsékb1 ribosomal protein B6 kinase, polypeptide 1 2.8 
Rpsékb2 ribosomal protein B6 kinase, polypeptide 2 2.2 
Uk1 Unc-51 like kinase 1 (C. elegans) 2.3 
Erbb Pathway 
A reg amphiregulin 57.5 
Ct Casitas B-lineage lymphoma 4.1 
Ctlc Casitas B-lineage lymphomac 2.3 2.5 
Ertb2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 3.1 2.6 
Ereg epiregulin 33.S 4.5 
Hbegf heparin-binding EGF-like growth factor 101S 
Nick2 non-catalytic region of tyrosine kinase adaptor protein 2 3.7 2.3 
Nrg1 neuregulin 1 3.9 4.2 
Nrg3 neuregulin 3 4.9 
Shc1 Src homolog 2 domain-containing transforming protein C1 6.5 
Shc4 SHC (Src homology 2 domain containing) family, member 4 5.5 
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TABLE 7-continued 
Components of signaling pathways overexpressed in Kras'-induced carcinomas 
SYMBOL NAME CN 
Src. Rous sarcoma oncogene 4.1 
Tgfa transforming growth factor alpha 7.6 
Wnt Pathway 
Axin1 axin 1 3.5 2.3 
CSnk2a1 casein kinase 2, alpha 1 polypeptide 3.4 
CSnk2a1 casein kinase 2, alpha 1 polypeptide 15.4 
CSnk2a1 casein kinase 2, alpha 1 polypeptide 2.5 
CSnk2a2 casein kinase 2, alpha prime polypeptide 3 
CSnk2a2 casein kinase 2, alpha prime polypeptide 2.4 
Ctanb1 catenin (cadherin associated protein), beta 1 4.7 
Ctanb1 catenin (cadherin associated protein), beta 1 2.4 
Ctnnbip1 catenin beta interacting protein 1 2.5 2.1 
Daam1 dishevelled associated activator of morphogenesis 1 3.3 2.6 
Dkk2 dickkopfhomolog 2 (Xenopus laevis) 5.4 8.3 
Dw11 dishevelled, dsh homolog 1 (Drosophila) 2 
Dw11 dishevelled, dsh homolog 1 (Drosophila) 2 
FZ2 frizzled homolog 2 (Drosophila) 14.5 
FZ2 frizzled homolog 2 (Drosophila) 3.5 
FZd6 frizzled homolog 6 (Drosophila) 2.3 
FZd6 frizzled homolog 6 (Drosophila) 2.5 
Lrp5 low density lipoprotein receptor-related protein 6 3.7 
Nfats Nuclear factor of activated T-cells 5 3.1 
Nfats nuclear factor of activated T-cells 5 2.5 
Nkd1 naked cuticle 1 homolog (Drosophila) 2.2 5.8 
Nkd2 Naked cuticle 2 homolog (Drosophila) 2.9 
Fpp2rla protein phosphatase 2 (formerly 2A), regulatory subunit A (PR55), alpha isoforme 2.4 
Prickle1 prickle like 1 (Drosophila) 14.8 3.6 
Prickle1 prickle like 1 (Drosophila) 2.7 2.6 
Prickle1 prickle like 1 (Drosophila) 3.2 
Prickle1 prickle like 1 (Drosophila) 5.9 
Ruwbl1 RuvB-like protein 1 2 
Senp2 SUMO?sentrin specific peptidase 2 2.2 
Sfrp1 secreted frizzled-related sequence protein 1 2.8 2.7 
Sfrp1 secreted frizzled-related sequence protein 1 5.8 5.4 
Sfrp1 secreted frizzled-related sequence protein 1 3 8.2 
Sfrp1 secreted frizzled-related sequence protein 1 3.9 12.1 
Tb1x transducin (beta)-like 1 X-linked 13.3 
Tb1x Transducin (beta)-like 1 X-linked 3 
Tcf72 Transcription factor 7-line 2, T-cell specific, HMG-box 3.2 
Vangl2 vang-like 2 (wan gogh, Drosophila) 3.2 2.4 
Wint10a wingless-related MMTV integration site 10a 4.5 4 
WintSa wingless-related MMTV integration site 5A S.1 3.4 
Wnt7b wingless-related MMTV integration site 7B 3.2 2.7 
Wnt7b wingless-related MMTV integration site 7B 4.1 3.6 
WintSa wingless-type MMTV integration site 5A 2.9 6.4 
Notoh Pathway 
Adam10 a disintegrin and metallopeptidase domain 10 2.5 
Adam17 a disintegrin and metallopeptidase domain 17 3.1 
Aph1a. anterior pharynx defective 1s homolog (C. elegans) 4 
D14 cells-like 4 (Drosophila) 2 
Dtx3 cellex 3-like (Drosophila) 2.1 
F1 four and a half domains 1 4.5 
Gcins2 GCNS general control of amino acid synthesis-like 2 (yeast) 2.7 
Hdse2 histone desacetylase 2 4.3 
HeS1 hairy and enhancer of split 1 (Drosophila) 2.7 
Jag1 jagged 1 7.6 S.1 
Jag2 jagged 2 2.3 2.3 
Nicor? nuclear receptor ca-repressor 2 3 
Notch1 Notch gene homolog 1 (Drosophila) 2.3 
Notch3 Notch gene homolog 1 (Drosophila) 6.1 2 
Snw1 SNW domain containing 1 4.5 
Tgrb Pathway 
Acwr1 activin A receptor, type 1 3.1 
Acwr1b activin A receptor, type 1B 2.1 
Acwr2a Activin receptor IIA 2.9 
Bmp7 bone morphogenetic protein 7 4 3.6 
Bmprlb bone morphogenetic protein receptor, type 1B 2.8 2.5 
Bmpr2 bone morphogenetic protein receptor, type II (serinethreonine kinase) 3.5 
Fst follistatin 4.1 
Id1 inhibitor of DNA binding 1 2.5 
Id4 inhibitor of DNA binding 4 5 2.1 
Inhba inhibin beta-A 2O2 5.7 
Smad1 MAD homolog 1 (Drosophila) 3.4 
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TABLE 7-continued 
Components of signaling pathways overexpressed in Kras'-induced carcinomas 
SYMBOL NAME CN 
Smad3 MAD homolog 3 (Drosophila) 2.1 
SmadS MAD homolog 5 (Drosophila) 3.1 
Smadf MAD homolog7 (Drosophila) 3.4 
Smurf1 SMAD specific E3 ubiquitin protein ligase 1 2.9 2.4 
Smurf2 SMAD specific E3 ubiquitin protein ligase 2 3.7 
Sp1 trans-acting transcription factor 1 5.7 
Tgfb1 transforming growth factor, beta 1 4.5 
Tgfb2 transforming growth factor, beta 2 2.4 3.7 
Tgfbr1 Transforming growth factor, beta receptor I 2.9 
Tgfbr2 Transforming growth factor, beta receptor II 2.2 
ThbS1 thrombospondin 1 i? similar to thrombospondin 1 5 
Thbs2 thrombospondin 2 3.5 6.3 
Jak Stat Pathway 
Ctcf.1 cardiotrophin-like crystalline factor 1 2.9 S.1 
Cntf cllary neurotrophic factor 2.5 
CSf2 calony stimulating factor 2 (granulocyte-macrophage) 2.1 2 
Csf3 calony stimulating factor 3 (granulocyte) 2.5 2.7 
Csf3r calony stimulating factor 3 receptor (granulocyte) 2.3 
Ingr2 interleukin gamma receptor 2 3.4 
II13ra1 interleukin 13 receptor, alpha 1 2.8 
II2Orb interleukin 20 receptor beta 4 13.5 
II23a interleukin 23, alpha subunit p15 3.3 2.6 
II24 interleukin 24 14.1 12.7 
II28ra interleukin 28 receptor alpha 3 
I4 ra interleukin 4 receptor, alpha 2.3 
I6 interleukin 6 2.2 2.5 
Jak3 Janus kinase 3 2.1 
Lif leukemia inhibtory factor 4.1 
Pias4 protein inhibtor of activated STAT 4 3.3 
Socs3 Suppressor of cytokine signaling 3 2.8 
SocSS Suppressor of cytokine signaling 5 3.6 2.2 
Spred1 sprouty protein alth EVH-1 domain 1, related sequence 3.5 
Spred2 sprouty-related, EVH1 domain containing 2 4.6 
Spred3 sprouty-related, EVH1 domain containing 3 6.3 2.5 
Stam2 Signal transducing adaptor molecute (SH3 domain and ITAM motif)2 3.4 2.4 
Hedgehog Pathway 
Cank1d casein kinase 1, delta 2.8 
Cank1g1 casein kinase 1, gamma 1 5 
Cank1g2 casein kinase 1, gamma 2 2.1 2 
Dhh desert hedgehog 4 
G3 GLI-Kruppel family member GLI3 2.2 
PtCl2 patched homolog 2 2.5 
Stk35 serinethreonine kinase 35 (fused homolog, Drosophila) 2.2 
Vegf Pathway 
Pxn paxlin 4.5 2.1 
Sphk1 sphingosine kinase 1 4.8 
Vegfa vascular endothelial growth factor A 2.5 2 
Vegfe vascular endothelial growth factor C 3 
Cell Cycle 
Anapcs anaphase-promoting complex subunit 5 2.2 
Bub1 budding uninhibited by benzimidazoles 1 homolog (S. cerevisiae) 10.3 
Bub1b budding uninhibited by benzimidazoles 1 homolog, beta (S. cerevisiae) 5.4 2.1 
Bub3 budding uninhibited by benzimidazoles 3 homolog (S. cerevisiae) 2.3 
Ccna2 cyclin A2 7.6 
Ccnb1 cyclin B1 17 2 
Ccnb2 cyclin B2 11.5 
Ccnd1 cyclin D1 10 
Ccnd2 cyclin D2 3 
Ccne2 cyclin E2 3.3 
Cdc20 cell division cycle 20 homolog (S. cerevisiae) 7.3 
Cdc23 CDC23 (cell division cycle 23, yeast, homolog) 5.5 
Cdc25c cell division cycle 25 homolog C (S. pombe) 3 2.2 
Colc2a cell division cycle 2 homolog A (S. pombe) 14.8 
Cdc45 cell division cycle 45 homolog (S. cerevisiae)-like 3.5 
Cdc6 cell division cycle 6 homolog (S. cerevisiae) 2.9 
Cdc7 cell division cycle 7 (S. cerevisiae) 2.1 
Cok4 cyclin-dependent kinase 4 3.1 
Cdk6 cyclin-dependent kinase 6 5.2 
Cdk7 cyclin-dependent kinase 7 (homolog of Xenopus MO15 colk-activating kinase) 2.3 
Cokn1a cyclin-dependent kinase inhibtor 1A (P21) 11.2 
Cdkn1b cyclin-dependent kinase inhibtor 1B 10.8 
Cdkn2b cyclin-dependent kinase inhibtor 2B (p15, inhibits CDK4) 5.4 
SYMBOL 
Chek1 
Dbfa. 
E2f1 
E23 
Espl1 
Fzr1 
Mad11 
Mad21 
Mcm2 
Mcm3 
Mcma. 
Mcms 
Mcmf 
Mcm2 
Orc1 
Orc2l 
Orc4 
Plt1 
Sfn 
Skp2 
Smc1a. 
Wee1 
Ywhag 
Ywhah 
YwhaZ 
Apafl 
Bad 
Bax 
Bcl21 
BIrc4 
Capn1 
Casp3 
Casp6 
1a 
11b 
11 rap 
rak2 
Ngfb 
Prkarla 
Prkar2a 
Tnfrsfl0b 
Tradd 
TrpS3 
Crebbp 
Cank1a1 
Cankle 
Ctbp2 
Fbow11 
Fos1 
Gsk3b 
Jun 
Myc 
Nfatc3 
Nfatca. 
NIk 
Ppp2cb 
Prkacb 
Prkca 
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TABLE 7-continued 
Components of signaling pathways overexpressed in Kras-induced carcinomas 
NAME 
checkpoint kinase 1 homolog (S. pombe) 
DBF4 homolog (S. cerevisiae) 
E2F transcription factor 1 
E2F transcription factor 3 
extra spindle poles-like 1 (S. cerevisiae) 
fizzyi cell division cycle 20 related 1 (Drosophila) 
mitotic arrest deficient 1-like 1 
MAD2 (mitotic arrest deficient, homolog)-like 1 (yeast) 
minichromosome maintenance deficient 2 mitotic (S. cerevisiae) 
minichromosome maintenance deficient 3 (S. cerevisiae) 
minichromosome maintenance deficient 4 homolog (S. cerevisiae) 
minichromosome maintenance deficient 5, cell division cycle 46 (S. cerevisiae) 
minichromosome maintenance deficient 7 (S. cerevisiae) 
transformed mouse 373 cell double minute 2 
origin recognition complex, Subunit 1-like (S. cerevisiae) 
origin recognition complex, Subunit 2-like (S. cerevisiae) 
origin recognition complex, Subunit 4-like (S. cerevisiae) 
polo-like kinase 1 (Drosophila) 
stratfin 
S-phase kinase-associated protein 2 (p45) 
structural maintenance of chromosomes 1A 
wee 1 homolog (S. pombe) 
3-monooxygenase tryptophan 5-monooxygenase activation protein, gamma 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, Zeta 
Apoptosis 
apoptotic peptidase activating factor 1 
Bcl-associated death promoter 
Bcl2-associated X protein 
Bcl2-like 1 
Baculoviral IAP repeat-containing 4 
calpain 1 
caspase 3 
caspase 6 
interleukin 1 alpha 
interleukin 1 beta 
interleukin 1 receptor accessory protein 
interleukin-1 receptor-associated kinase 2 
nerve growth factor, beta 
protein kinase, cAMP dependent regulatory, type I, alpha 
protein kinase, cAMP dependent regulatory, type II alpha 
tumor necrosis factor receptor Superfamily, member 10b 
TNFRSF1A-associated via death domain 
transformation related protein S3 
More than one Pathway 
CRES binding protein 
casein kinase 1, alpha 1 
casein kinase 1, epsilon 
C-terminal binding protein 2 
F-box and WD-40 domain protein 11 
fos-like antigen 1 
glycogen synthase kinase 3beta 
Junoncogene 
myelocytomatosis oncogene 
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 
Nemo like kinase 
protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform 
protein kinase, cAMP dependent, catalytic, beta 
protein kinase C, alpha 
CN 
6.7 
4.2 
2.4 
2.1 
3.4 
2.3 
2.2 
2.6 
2.5 
2.9 
2.7 
3.7 
2.2 
4.1 
2.1 
2.7 
10 
11 
4.9 
2.1 
2.1 
3.8 
2.6 
3.4 
4.7 
3.4 
2.8 
S.6 
9.4 
2.5 
3.3 
13 
4.5 
8.6 
3.2 
2.3 
2.2 
2.8 
4.8 
5.5 
S.1 
10.1 
2.3 
3.6 
9.2 
6.2 
4.8 
2.4 
3.4 
2.4 
4.3 
2.3 
3.6 
2.4 
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2.1 
2.8 
2 
3.2 
2.2 
2 
3.9 
4.7 
2.2 
2 
3.5 
2.5 
2.2 
4.6 
2.1 
2.3 
C/N is the ratio or the level of expression in Kras tumors over normal mammary glands. The same ratio was calculated in tumors that eventually 
developed after ablation of Igflr. The fold differences between the two ratios for genes that were upregulated () on downregulated () in the absence 
of IGF signaling is indicated, 
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Conditional Ablation of Igflr Delays Kras-induced Mam 
mary Tumorigenesis 
One of the most interesting changes detected in Kras 
induced mammary cancers by RNA profiling was an 
increased expression of Igflr, which was confirmed by North- 5 
ern analysis. This prompted an investigation about the poten 
tial involvement of IGF signaling in the development of mam 
mary tumors in this mouse model. 
A compelling reason for asking this question is evidence in 
the prior art Suggesting that cells lacking Igflir cannot be 10 
transformed by any one of several tested oncoproteins 
(Baserga, Expert Opin. Ther. Targets (2005), 9, 753-68). 
Apparently, Igflr-mediated signaling is not an oncogenic 
component per se, but a crucial prerequisite for oncogenesis 
considering that, among other effects, it provides a necessary 15 
and strong antiapoptotic signal for tumor growth. The Igflr 
gene is neither amplified nor obligatorily overexpressed in 
human breast cancer. Thus, despite reported cases of overex 
pression, it is not uncommon to detect Igflr mRNA levels that 
are equal or even lower in cancer cells than in normal breast 20 
tissue (Chong et al., Anticancer Res. (2006), 26(1A), 167-73). 
Nevertheless, it is interesting that 36% of examined basal-like 
breast cancers (n=64) were shown by immunohistochemistry 
to be Igflr-positive (Lerma et al., Mod. Pathol. (2007), 20, 
1200-07). 25 
To examine the impact of the absence of Igflr on the 
development of mammary tumors induced by Kras overex 
pression, tumorigenic progression was compared between 
animals carrying the oncogenic transgene in a background 
either wild-type for Igflr (Eefla1-Kras/Wapcre mice serv- 30 
ing as controls) or possessing one or two floxed Igflralleles 
that could be conditionally ablated (Eeflal-Kras/Wapcre? 
Igflr" and Eefla1-Kras/Wap/Igflr'? genotypes; n=11 
and n=14, respectively). 
It was observed that, in contrast to cancer manifestation 35 
after the first birth with a T50 of 9 days in control mice, 
ablation of both floxed Igflralleles in experimental animals 
resulted in tumor development only after three pregnancies, 
while the latency increased dramatically (11-fold; T50=101 
days; P<0.0001, log-rank test; FIG. 1D). However, complete 40 
rescue was not observed, perhaps owing to the occurrence of 
mutational and/or epigenetic alterations compensating for the 
absence of IGF signaling (Southern analysis confirmed that 
Cre-mediated recombination had occurred in the Igflr locus, 
while the tumors lacked Igflrexpression detectable by immu- 45 
nohistochemistry or by Northern/Western analysis; data not 
shown). Immunostaining for all examined markers (including 
pAkt, pFrk1/2 and pS6) was virtually unaltered in the 
Igflr-/- tumors, while significant differences in the multifo 
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cality and overall size of the carcinomas or in the proliferation 
indices of the components were not noted (Table 3). On the 
other hand, with the exception of SRC, significant alterations 
were observed in the relative sizes of the components (Table 
3). Interestingly, absence of only one Igflr allele (Eefla 1 
Kras/Wap"/Igflr' animals) also resulted in a statistically 
significant delay in tumor appearance after a first pregnancy 
(-5-fold increase in latency; P=0.01; FIG. 1D). 
Comparison of the expression profiles of Kras cancers 
developing in the presence or absence of Igflr signaling 
revealed, among other effects (Table 9), significant differ 
ences in transcript levels for Egfligands that were confirmed 
by Northern analysis. Specifically, with intact Igflr, there was 
>100-fold increase over normal in the amount of steady-state 
mRNA for Hbegf present in the tumors, while the levels of 
overexpressed transcripts for Areg, Ereg and Tgfa were less 
dramatic (~4-, 15- and 6-fold, respectively). Interestingly, a 
similar overexpression of Egf ligands was observed in an 
HrasG12V breast cancer model (Sarkisian CJ, et al. Nat. Cell 
Biol. (2007), 9:493-505), implying a more general feedback 
loop involving Ras protein function. It was found that elimi 
nation of Igflr only slightly affected the overexpression of 
Areg, but resulted in the reduction of the Ereg and Tgfa 
transcripts to almost normal levels, while the previously enor 
mous amount of Hbegf mRNA was reduced approximately 
by half. In contrast, Igfl and Igf2 transcripts encoding IGF 
ligands were virtually absent from the tumors and Igfl and 
Igf2 polypeptides were below detection limits by immuno 
histochemistry (Table 4) indicating absence of IGF autocrine/ 
paracrine signaling cues. Accordingly, unless it is eventually 
found that Igflr-mediated signaling is triggered by EGF 
ligands acting through non-canonical IGF1R-EGFR het 
erodimers (Riedemann, J., et al., Biochem. Biophys. Res. 
Commun. (2007), 355, 707-714), it is likely that the IGF 
functions are served in the Kras mammary cancers by endo 
crine action of IGF1 circulating in serum. Assuming this to be 
the case, it appears that IGF signaling potentiates Erbb-me 
diated activities by upregulating Egf ligands through an 
unknown mechanism, which could be transcriptional and 
could involve Ap1 sites present in the promoter regions of 
some of these ligands (Ornskov D, et al., Biochem. Biophys. 
Res. Commun. (2007), 354:885-891). Interestingly, Fos11, an 
Ap1 component, is highly overexpressed in the Kras' tumors 
(FIG. 6 and Table 4). Three of the four Erbb receptors (Egfr, 
Erbb2 and Erbb3) are present in the Kras tumors, but they 
are not overexpressed. In fact, Erbb2 transcripts remain unde 
tectable by Northern analysis, although the receptor itself can 
be seen in the carcinomas by immunostaining (FIG. 6). 
TABLE 9 
List of primary antibodies 
Antigen Source Name/Clone': Catalog No. Retrieval Incubation 
CK18 (Krt18) Abcam, Cambridge, MA Clone C-04; ab668 H6.O 1 h RT, 1:200 
ER Santa Cruz Biotechnology, Santa Cruz, CA Polyclonal (Rb); sc-543 Ole 1 h RT, 1:400 
PR ABRAffinity Bioreagents, Golden, CO Clone PR-AT 4.14; MA1-410 pH6.0 O/N 4° C., 1:50 
Gata Santa Cruz Biotechnology, Santa Cruz, CA Polyclonal(Gt); sc-1236 H6.O O/N 4° C., 1:100 
CK5 (Krt5) Cowance, Princeton, NJ 
CK14 (Krt14) Covance, Princeton, NJ 
Polyclonal (Rb); PRB-16OP H6.O 1 h RT, 1:500 
Polyclonal (Rb); PRB-155P H6.O 1 h RT, 1:500 
SMA (Actg2) Dako, Carpinberia, CA Clone 1A4; MO85129 H6.O O/N 4° C., 1:200 
p63 (Trp63) BD Pharmingen, San Diego, CA Clone 4A4: 559951 H6.O O/N 4° C., 1:500 
Itga.6 Santa Cruz Biotechnology, Santa Cruz, CA Polyclonal(Gt); sc-6596 H6.O O/N 4° C., 1:50 
Itgb1 Millipore Corp, Billerica, MA Clone P4G11; MAB-1951 Ole O/N 4° C., 1:50 
CD24 BD Pharmingen, San Diego, CA Clone M1/69; 557436 H6.O 1 h RT, 1:200 
CK6 (Krtó) Cowance, Princeton, NJ Polyclonal (Rb); PRB-169P H6.O 1 h RT, 1:200 
Nestin DSHB, Iowa City, LA Clone Rat 401c H6.O O/N 4° C., 1:50 
Annexin VIII Santa Cruz Biotechnology, Santa Cruz, CA Polyclonal (Rb); sc-28825 H6.O O/N 4° C., 1:200 
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List of primary antibodies 
Antigen Source Name/Clone': Catalog No. 
Sca1 Cedarlane Labs, Homby, ON Clone CT-6A/6E: CL8934AP 
pErk Cell Signalling Technology, Danvers, MA Clone E10;9106 
pAkt1 Cell Signalling Technology, Danvers, MA Polyclonal (Rb); 9277 
pS6 Cell Signalling Technology, Danvers, MA Polyclonal (Rb): 2211 
Igflr Cell Signalling Technology, Danvers, MA Polyclonal (Rb): 3027 
Igf1 Dr. Louis E. Underwood 
Igf2 Upstate Biotechnology, Lake Placid, NY Clone S1 F2: 05-166 
Egfr Cell Signalling Technology, Danvers, MA Polyclonal (Rb); 2232 
Erbb2 (Neu) 
Erbb3 
Santa Cruz Biotechnology, Santa Cruz, CA 
BD PharMingen, San Diego, CA 
Polyclonal (Rb); sc-284 
Clone RTJ.1.554208 
Fos1 Santa Cruz Biotechnology, Santa Cruz, CA Polyclonal (Rb); sc-605 
Casp3(Asp175) Cell Signalling Technology, Danvers, MA Polyclonal (Rb);9661 
KI-67 Novus Biologicals, Littleton, CO Clone SP6; NB110-57147 
E-cadherin BD Biosciences, San Jose, CA Clone 36: 610182 
B-catenin BD Biosciences, San Jose, CA Clone 14: 610153 
Vimentin Fitzgerald Industries, Concord, MA Polyclonal(Gp); PROGP53 
Retrieval Incubation 
:50 
:50 
:50 
:200 
:200 
:200 
:50 
:100 
:200 
:200 
:100 
:200 
:100 
:500 
:100 
:500 
Rb: rabbit; Gt: goat; Gp: guinea pig 
pH6.0: antigen retrieval by boiling 15 minutes in 0.01M citrate buffer pH6.0 
pH7.5: antigen retrieval by boiling 15 minutes in 0.01 MEDTA pH7.5 
ON: overnight; RT: room temperature 
Pharmacological Treatment of Kras-induced Mammary 
Tumors 
The strong genetic evidence for an Igflr role in mammary 
tumorigenesis at least in the examined model is significant in 
the context of efforts to develop therapeutic approaches for 
treating breast cancer by blocking of IGF signaling. This 
could turn out to be significant for basal-like carcinomas, 
which have poor prognosis (Sorlie T, et al. Proc. Natl. Acad. 
Sci. USA (2001), 98: 10869-10874) and pose a serious prob 
lem to targeted therapies (Cleator S, et al., Lancet Oncol. 
(2007). 8:235-244; Carey L. A. et al., Clin. Cancer Res. 
(2007), 13:2329-2334), considering that the use of antiestro 
gens in combination with trastuzumab (anti-ERBB2 anti 
body) is not an option, while there is no clear choice for 
chemotherapy. Therefore, the Kras model was used in a 
preclinical study testing the efficacy of the cyclolignan 
picropodophyllin (PPP), which has recently emerged as a 
potent, nontoxic and highly specific Igflr inhibitor (Girnita, 
et. al., Cancer Res. (2004), 64,236-42). Although the molecu 
lar mechanism of PPP action is still unknown, its inhibitory 
effects appear to be exerted by abrogation of Igflr phospho 
rylation and promotion of its degradation, while the homolo 
gous insulin receptor is not affected (Girnita, et. al., Cancer 
Res. (2004), 64, 236–42; Vasilcanu, et al., Oncogene, (2008), 
27: 1629-1638). Cell lines of Igflr null fibroblasts are appar 
ently insensitive to PPP, whereas the drug reduces the viabil 
ity of cancer cell lines and causes tumor regression in mouse 
Xenografts of multiple myeloma (Menu et al., Int. J. Cancer 
(2007), 121, 1857-61) and uveal melanoma (Girnita et al., 
Clin. Cancer Res. (2006), 12, 1383-91). Therefore, the Kras 
model described herein was used for testing the potential 
therapeutic effects of PPP on breast cancer. For this purpose, 
PPP was administered either alone or in combination with 
erlotinib, an Egfrinhibitor (Yang SX, et al., Clin. Cancer Res. 
(2005), 11: 6226-6232), taking into consideration the over 
expression of Erbbligands and Igflr/Egfr signaling relation 
ships described above. 
Miceata progressed stage of tumorigenesis bearing at least 
one readily palpable tumor were injected intraperitoneally 
once daily either with vehicle or with PPP and Erlotinib, 
alone or in combination, at doses of 30 mg/kg and 50 mg/kg, 
respectively, for a period of 3 weeks, considering that the 
weight of Some tumors in the controls could reach or exceed 
25 
30 
35 
40 
45 
50 
55 
60 
65 
~1 g by that time. At the end of treatment, we measured tumor 
growth relative to control values by calculating tumor mass, 
and we did not attempt sequential measurements using a 
caliper because a pilot study indicated that they were inaccu 
rate. First, the tumors developing in each gland tended to be 
multifocal and uneven, and progressively coalesced into 
larger masses precluding reliable evaluation. In addition, the 
treatment resulted in extensive tumor necrosis and fibrosis 
detectable only histologically, which would have artificially 
inflated macroscopic measurements. 
All glands carrying tumors in treated and control animals 
were analyzed, and for statistical evaluation, it was taken into 
account that the cancers exhibited pronounced size heteroge 
neity (see FIGS. 3A-3F). On average, either Erlotinib or PPP 
was effective and did not permit expansion of tumor Volume 
per mammary gland beyond a level of -30% and ~7% of the 
control value, respectively (Table 6). The effect of the drugs 
used in combination (~4% of control) was perhaps only addi 
tive (dose-response relationships were not yet studied). 
Monitoring of body weights and histological examination of 
various organs from vehicle- and drug-treated mice did not 
reveal signs of non-specific toxicity. 
TABLE 6 
Drug treatments 
Mice 
(n) 
Glands 
(n) 
Tumor volume 
per gland (mm) % Pb 
Mouse Tumors 
Vehicle 
Erlotinib 
PPP 
PPP - Erlotlib 
Xenografts 
21 217.8 65.6 
16 66.9 29.3 
17 16.0 9.1 
18 8.63.9 
100 
30.7 
7.3 
3.9 
Vehicle 
PPP 5 
5 304 40.8 
215 - 18.6 
100 
70.7 O.O2 
Mean S.E.M. 
Because of data skewness, in tumor volume comparisons between the drug treatments and 
the control (vehicle), probabilities (P) were calculated using Student's t-test after logarith 
mic transformation of the values to meet the distribution criterion of the test. 
Not unexpectedly, vehicle administration did not alter the 
histopathological or immunophenotypic profile of tumors, 
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whereas the specimens of mice treated either with PPP or with 
a PPP/Erlotinib combination displayed a marked reduction or 
even absence of the pale and squamous cell components 
accompanied by extensive keratinization and vacuolation 
(FIGS. 3A-3F). Thus, small cancerous lesions observed post 
treatment consisted only of glandular and spindle cell types. 
The extent of the latter, however, which exhibited degenera 
tive changes, is difficult to quantitate. Erlotinib acting alone 
reduced predominantly the pale cell component. However, 
residual squamous cell carcinomas, whenever encountered 
together with glandular and spindle cell components, exhib 
ited extensive degenerative changes and marked tumor necro 
S1S. 
To ascertain whether the reduction in tumor volume was a 
consequence of decreased proliferation or increased cell 
death, proliferation indices were determined, and as a mea 
Sure of apoptosis, the expression of activated caspase-3 after 
only 3 days of PPP or PPP plus Erlotinib treatment, i.e. prior 
to a drastic decrease of the pale and squamous cell compo 
nents was examined. It was observed that, while proliferation 
was still at control levels, the numbers of caspase-3-positive 
cells in the microacinar and non-glandular components were 
2- and 9-fold higher, respectively, than in controls (FIG. 3C). 
To evaluate IGF1R as a drug-target in human cells, the 
receptor in MDA-MB-231 mammary cancer cells, which 
possess a KrasG13D mutant gene (Kozma SC, et al., Nucleic 
Acids Res. (1987), 15:5963-5971; Hollestelle A, et al., Mol 
Cancer Res. (2007), 5:195-201) and share similarities in tran 
scriptional profile with basal-like mammary tumor cell line 
(Charafe-Jauffret E, et al., Oncogene (2006), 25:2273-2284) 
was targeted. Pharmacological inhibition using PPP drasti 
cally reduced the in vitro viability of MDA-MB-231 cells 
(FIG. 8A). In addition, IGF1R knockdown using either a 
dominant-negative form of the receptor or siRNA had an 
analogous effect (FIGS. 8B and 8C). In a xenograft model in 
NOD/SCID mice, it showed that tumor growth from orthoto 
pically injected MDA-MB-231 cells was also attenuated in 
PPP-treated mice in comparison with vehicle-treated controls 
(Table 6). Although the in vivo effect of PPP on the highly 
invasive MDA-MB-231 xenografts was overall less pro 
nounced than that observed with the mouse carcinomas, it 
was statistically significant. In addition to other factors. Such 
as poor vascularization making the drug less accessible, the 
behavior of these xenografts derived from MDA-MB-231 
cells that are more spindly than epithelial may be analogous to 
the relatively reduced response of the SRC component of 
mouse Kras tumors to PPP. Nevertheless, in conjunction 
with the mouse data, these observations provide strong justi 
fication for further evaluations of the drug against human 
breast cancer. 
KRAS and Human Breast Cancer 
A comparison between the mouse mammary tumors 
induced by K-rasactivation and human breast cancer is 
shown in FIGS. 5A-5D. In a set of human breast cancer 
specimens collected in the period between 1994 and 2003, 
1794 (18%) were found to be basal-like (triple-negative), 
while 77/64 (82%) were non-basal. Analysis of the 17 basal 
cancers for KRAS amplification by using Southern blotting, 
CGH and FISH showed that 5 of the specimens (-29%) 
scored positive in at least two of these three assays (FIGS. 
5E-5G show an example of the FISH results), whereas ampli 
fication of the locus (detected by CGH) was found in only 4 of 
the 77 non-basal samples (-5%; P=0.008, Fisher's exact test). 
All 5 basal-like specimens with amplified KRAS displayed 
medullary features, as they formed large tumor nodules with 
pushing, rather than infiltrative borders and were composed 
of large cells with irregular, sometimes bizarre nuclei grow 
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ing in a syncytial fashion consistently lacking tubule forma 
tion. However, none of these carcinomas metall of the criteria 
for medullary carcinoma and, thus, they are referred to here as 
"atypical medullary breast cancer (AMBC). Interestingly, 3/s 
AMBCs with KRAS amplification, which in addition to their 
syncytical/nodular growth pattern contained high numbers of 
large cells with pale or clear cytoplasm, exhibited a strong 
resemblance to the histomorphological signature of the pale 
cell carcinoma observed in our mouse model. To confirm the 
validity of this correlation, all of the available triple-negative 
ABMCs (n=9) collected between 2005 and 2007 were exam 
ined, and it was observed that most of them (%) were at least 
focally comparable to the PCC in Kras mice. Immunohis 
tochemical analysis showed that all 9 of these ABMCs were 
positive for basal cytokeratins 5 and 14 and showed IGF1R 
staining along their cellular Surface. FISH analysis was then 
performed to assess potential amplification of the KRAS 
locus and found that 3 of these cancers, all of which possessed 
as a major component large pale cells, tested positive 
(P=0.02; using the data 3/9 for basal and /77 for non-basal 
specimens). These data indicate that a Subset of basal-like 
human breast cancers exhibit preferentially amplification of 
the KRAS locus frequently associated with a pale cell carci 
noma character. 
8.3. Conclusion 
It has been shown that overexpression of oncogenic Kras 
in mouse mammary glands leads to rapid development of 
histopathologically heterogeneous malignant tumors pre 
dominantly simulating human basal-like breast cancers, but 
also including a luminal type. Although the incidence of 
KRAS mutations in human breast cancer is not very high, it is 
still appreciable (~7% in tumors and ~13% in cancer cell 
lines; see Hollestelle A, et al., Mol. Cancer. Res. (2007), 
5:195-201; Malaney Sand Daly R.J.J. Mammary Gland Biol. 
Neoplasia (2001), 6:101-113). Moreover, in-70% of primary 
breast cancers, the level of RAS is higher than that in normal 
tissue (Dati C, et al. Int. J. Cancer (1991). 47:833-838). Such 
elevated RAS activity is apparently required even for mam 
mary carcinogenesis induced by RAS mutations (Sarkisian C 
J, et al. Nat. Cell Biol. (2007), 9:493-505). Clearly, regardless 
of cause (mutation and/or overexpression), the important ele 
ment contributing to oncogenesis is the perturbation of the 
Ras pathway, which can be dissected genetically by mouse 
modeling. The diversity of cancerous forms and especially 
the rapidity of tumor manifestation increases further the util 
ity of the mouse model that have been described here, which 
can be used advantageously after appropriate genetic testing 
for preclinical evaluation of treatment regimes, as exempli 
fied by our results. 
Seemingly, the single-step tumorigenesis that has been 
observed does not conform to the widely accepted multi-hit 
model of carcinogenesis (Vogelstein B and Kinzler K W. 
Trends Genet. (1993), 9:138-141; Hanahan D and Weinberg 
R.A, Cell (2000), 100:57-70). However, from the standpoint 
that cancer is a disease of malfunctioning cell signaling, all 
cases of tumor development can be viewed, regardless of 
timing, as variants of a more general hypothesis positing that 
contributing “hits’ correspond to recruitment and combina 
torial engagement of deregulated pathways predominantly 
involved in apoptosis and growth control. Apparently, in the 
case of our model, highly overexpressed, constitutively active 
Kras can elicit synergism of downstream pathways that are 
simultaneously deregulated to a degree Sufficient for rapid 
development of invasive cancer. Analogous inverse reciproc 
ity between Kras expression levels and tumor latency in 
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other mouse models has been observed other than the 
extremely rapid development of carcinomas of the skin and 
the oral mucosa induced by Kras observed by others (Vitale 
Cross L., etal, Cancer Res. (2004), 64:8804-8807). It remains 
to be seen whether, by exceeding normally affordable limits, 5 
oncogene overexpression overrides homeostatic capabilities 
and/or if the excessive deregulation that it causes permits 
novel and abnormal signaling interactions. 
An additional open question is why the constitutively act 
ing oncogenic Kras, which has ceased to respond to 10 
upstream effectors in signaling relays and has presumably 
acquired autonomy in deregulating signaling, is not refrac 
tory to the silencing of Igflr. Ras proteins control prolifera 
tion through the Raf->MEK->Erk pathway, but also interact 
directly with the p110 catalytic subunit of the PI3K complex, 15 
thus affecting anti-apoptosis. It is notable, in this regard, that 
loss-of-function missense mutations in the Ras binding 
domain of p110 inhibit almost completely Kras and Hras 
oncogenicity in mouse models of lung and skin tumors, 
respectively (Gupta S, et al. Cell (2007), 129:957-968). The 20 
mechanistic details in this case (involving a different tissue) 
are unclear. However, a testable hypothesis is that, without the 
crucial participation of Igflr signaling that exerts both PI3K 
dependent and PI3K-independent anti-apoptotic effects, the 
direct activation of the PI3K pathway by Kras is, despite its 25 
overexpression, inadequate for attaining a level of anti-apo 
ptosis able of promoting oncogenicity. It is noted that the 
results of a previous study (Cristofanelli et al. Oncogene 
(2000), 19:3245-3255) showing that 32D cells could become 
tumorigenic by the combined action of Hras and Irs1 (a down- 30 
stream effector of Igflr), but not by either one of these com 
ponents acting alone, could also be interpreted as indicating a 
collaboration between the Erk and PI3K pathways. Perhaps, 
among other effects, Kras triggers in this case the operation 
of a positive feedback loop that enhances its action through 35 
the upregulation of Igflr expression which, in turn, could 
amplify proliferative and anti-apoptotic signaling by increas 
ing the expression of Egfligands. The downregulation of such 
ligands by genetic inactivation of Igflr could explain why 
PPP is more effective than Erlotinib in the treatment of Kras - 40 
induced tumors. Presumably, pharmacological inhibition of 
Egfr alone does not attenuate tumor growth sufficiently 
because the Egfligands are still expressed at high levels and 
can function through other receptors of the family (the most 
likely candidates are Erbb2: Erbb3 heterodimers). In contrast, 45 
in addition to the direct pharmacological inhibition of Igflr 
activity by PPP, there is an indirect effect on Egf ligand 
downregulation preventing the robust formation of homo or 
heterodimers between the Erbb receptor family members. 
50 
9. EXAMPLE 4 
In Vivo Testing 
Mice were generated that carried the Ef1/Kras oncogenic 55 
mutation together with one or two alleles of the IGF1R locus 
conditionally knocked out (Xuan et al., J. Clin. Invest. 2002, 
110, 1011-19) and the WAPcre transgene (which would acti 
vate the oncogene and ablate the IGF1R gene in the same cells 
during pregnancy/lactation). Parous mice were observed for 60 
the development of invasive tumors and compared the tumor 
latency with control females that carried only the oncogene 
and the WAPcre gene. In such mice, IGF1 Rinactivation has a 
profound effect on tumor latency, even in mice where only 
one of the two alleles is ablated. 65 
To test the effect of IGF1RK inhibitors on tumor growth, 
parous Efl/Kras: WAPcre mice are monitored for tumor 
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development every day upon parturition and examined with 
palpation for tumor development. Once tumors are readily 
palpable (1-2 mm diameter), the tumor size and body weight 
of the mice are documented. Mice are then treated with either 
vehicle or an IGF1RK inhibitor. Typically, mice are injected 
daily with 100-150 ul of a solution containing 90% DMSO 
and 10% of an emulsifier (Cremophor EL, Sigma). In this 
solution, for example, PPP is completely soluble at a concen 
tration of 6 mg/ml. 
After 21 days of treatment, the mice are sacrificed, 
weighed, and the initial tumors measured individually. In 
addition, tumors which were not palpable at the time of initial 
palpation, but had grown during the therapy period, are also 
isolated. In an experiment comparing vehicle treatment with 
PPP, the total tumor volume per mouse in the vehicle group 
was 653+219 mm (number of mice: 7, total mammary gland 
affected: 21). Mice treated with PPP showed a much slower 
tumor growth with a total tumor volume per mouse of 54+28 
mm (p=0.05) at the end of the study. 
10. EXAMPLE 5 
10.1. Materials and Methods 
Mice 
Knock-in transgenic mice conditionally expressing onco 
genic Kras were generated by standard procedures using tar 
geted W9.5 ES cells. The targeting vector was prepared using 
the Eefla 1 cassette described in FIG.1. The starting DNA to 
provide homology arms (5'812 bp: 3' 3,606 bp) was a 4.418 
bp SacII/Nhel fragment containing the entire Eefla 1 locus 
except for the non-coding exon1. This fragment, isolated 
from a genomic library of mouse strain 129/Sv in phage w 
(WFIX II vector; Stratagene), was modified by introducing 
into a unique Spel site proximal to the end of intron 1 a 
PacI/PmeI/AscI linker to facilitate cloning. A mouse Kras 
cDNA (referred to here as Kras) containing a G-> A nucle 
otide substitution in codon 12 (GGT->GAT) was excised 
from a plasmid (pBS.K.S.G12D.Ras4B.p.A. kindly provided 
by Drs. D. Tuveson and T. Jacks, Massachusetts Institute of 
Technology, Cambridge, Mass.) and Subcloned into the 
pBigT vector (Srinivas S, et al., BMC Dev. Biol. (2001), 1:4). 
A segment from this intermediate construct containing a 
splice acceptor site, a floxed Pgk-neo-triple poly(A) and the 
Kras cDNA was excised as a PacI/AscI fragment and cloned 
into the corresponding sites of the PacI/PmeI/AscI linker 
described above. 
Molecular Analysis 
Standard protocols were followed for Southern, Northern 
and Western analyses. The probes used were a 616 bp Xbal/ 
SacII fragment immediately upstream from the 5' arm (South 
ern) and the Kras cDNA described above (Northern). The 
anti-Kras-specific antibody used for Western analysis was 
sc-521 (Santa Cruz, Biotechnology). To examine the effects of 
dominant-negative IGF1R, plasmid 486Stop (D’Ambrosio 
C, et al., Cancer Res. (1996), 56:4013-4020; kindly provided 
by Dr. R. Baserga, Thomas Jefferson University, Philadel 
phia) or control pcDNA3 plasmid were introduced into 
MDA-MB-231 cells grown in DMEM supplemented with 
10% fetal bovine serum by using a nucleofector (Amaxa 
Biosystems). RNA interference experiments with MDA-MB 
231 cells were performed as described (Rochester Mass., et 
al., Cancer Gene Ther. (2005), 12:90-100) using the siRNA 
duplex R4 sense strand 5'CAAUGAGUACAACUAC 
CGCTT3' (SEQ ID NO: 1); antisense strand 5'GCGGUAG 
UUGUACUCAUUGTT3' (SEQ ID NO: 2), which targets 
the human IGF1R mRNA at nucleotides 639-657, and a 
scrambled control duplex Scra; sense strand 5' GUCACAC 
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CGAUAAGUCACATT3' (SEQ ID NO:3); antisense strand 
5*UGUGACUUAUCGGUGUGACTT3' (SEQID NO:4). 
Histological Analysis, Immunophenotyping, Flow Cytom 
etry and FISH 
Mouse tissues were fixed in 10% formalin, embedded in 
paraffin, sectioned, and stained with hematoxylin and eosin. 
The primary antibodies and the conditions used for immuno 
histochemistry are listed in Table 9. Semiquantitative scoring 
(- to +++) was according to the system used for HercepTestTM 
(Dako), with - representing no staining, + weak staining 
in >15% of the cells, ++ strong focal staining in <15-20% of 
the cells, and +++ strong staining in >15-20% of the cells. 
Immunofluorescence was performed on paraffin sections by 
standard procedures. For flow cytometry, single cell Suspen 
sions from mammary glands and tumors prepared as 
described (Stingl J, et al. Nature (2006), 439:993-997) were 
processed using the EasySep kit (StemCell Technologies) 
and analyzed on a FACS Aria instrument (Becton Dickinson). 
For fluorescence in situ hybridization analysis we used three 
BAC clones (Invitrogen; RP11-157L06, RP11-583L24 and 
RP11-707G18) spanning the human chromosome 12p12.1 
region containing the KRASlocus. BAC DNA was labeled by 
nick-translation using spectrum redd UTP fluorochrome (Ab 
bott Molecular). A Spectrum green-labeled centromeric 12 
(CEP 12) probe (Abbott Molecular) was used to enumerate 
chromosome 12. FISH was performed by standard methods 
and hybridization signals were scored on at least 100 inter 
phase nuclei on DAPI-stained slides. The human breast can 
cer specimens analyzed histologically or by FISH were 
obtained from Surgical Pathology files of the College of Phy 
sicians, Columbia University, following approval of the Insti 
tutional Review Board. 
Microarray Analysis 
For expression profiling, total RNA was extracted from 
mammary tumors of Kras/WAP-cre bitransgenic or age 
matched postinvolutional female mice. The samples were 
profiled individually. For each assay, 5-8 ug of total RNA 
were used to generate biotinylated cRNA that was frag 
mented (15 ug) and then hybridized to Mouse Genome 430 
2.0 Array DNA Chips (Affymetrix). The microarrays were 
scanned (Affymetrix Scanner) and expression values for the 
genes were determined using Affymetrix GeneChip Operat 
ing Software 1.2. Filtering and further analysis using the raw 
data was performed with GeneSpring 6.0 software. A ratio of 
22 (experimental/control for “upregulated and control/ex 
perimental for “downregulated entries) was used as a widely 
accepted cut-off point indicative of a significant difference in 
transcript levels. An unsupervised clustering dendrogram was 
generated by using Cygwin Software. Literature data com 
pared with our results (see Table 5) were filtered to select and 
use only markers represented in the Affymetrix 430 2.0 chip, 
which also corresponded to known genes (unknown EST's 
were ignored) and were at least 2-fold upregulated or down 
regulated in comparison with corresponding controls. For 
comparative identification of signaling molecules (see Tables 
6 and Table 7), key-members of all major signaling pathways 
were listed in Table 8) and they were selected in a non 
redundant fashion from the following databases: KEGG (www.genome.ad.jp/kegg/kegg2.html), BioCarta (c.gap.n- 
ci.nih.gov/Pathways/BioCarta Pathways), Cancer Cell Map 
(cancer.cellmap.org/cellmap), Pathway-Express (Vortex.c- 
S.wayne.edu/ontoexpress) and Wikipathways (www. 
wikipathways.org). 
Statistical Analysis 
Values were expressed as meantS.E.M. Results were con 
sidered as statistically significant if P-0.05. For analysis of 
Survival curves, a log-rank test was used. Differences 
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between groups were examined using Student's t test. The 
null hypothesis that there is no marker difference in pairwise 
comparisons between microarray datasets was evaluated 
using Fisher's exact test. 
10.2. Results and Discussion 
Example3 has shown that the Kras-induced murine mam 
mary carcinomas are histopathologically heterogeneous and 
include, in addition to three basal-like components, a luminal 
type. On the basis of morphological and molecular criteria, an 
advanced hypothesis is that the cells-of-origin of the basal 
like carcinomas are epithelial progenitors. This is consistent 
with observations indicating that populations of flow-sorted 
CD24"/CD29' or CD24"/CD49f' cells (depleted of hemato 
poietic contaminants; Lin), which were enriched in mam 
mary gland-forming stem cells defined operationally by 
cleared fat pad transplantation assays (Shackleton M, et al., 
Nature (2006), 439:84-88; Stingl J, et al., Nature (2006), 439: 
993-997), exhibit phenotypic similarities with basal-like 
tumors (Asselin-Labat M L, et al., J. Natl. Cancer Inst. 
(2006), 98:1011-1014). Interestingly, comparative FACS 
analysis of cell Suspensions isolated from Kras-induced 
tumors (n-3) and normal mammary glands of age-matched 
parous females (n=5) showed an increase in the number of 
CD24"/CD49f" neoplastic cells (FIG. 9); the distribution of 
the markers CD49f (Itgao; integrin C.6) and CD29 (Itgb1; 
integrin B1) in Kras tumors is shown in FIG. 10). An addi 
tional interesting marker present in PCC and SCC, but not in 
SRC or Dunn tumors, was Scal (FIG. 6 and Table 4). 
Although CD24"/CD49f" cells express high levels of Scal 
only after culturing (Vaillant F, et al., Stem Cell Rev. (2007), 
3:114-123), this marker still belongs to a stem cell signature, 
considering that cultured mammary epithelial cells with this 
phenotype are able to repopulate cleared fat pads (Welm B E. 
et al., Dev. Biol. (2002), 245:42-56). Nevertheless, the obser 
vations are not sufficient to identify exact cell types and their 
hierarchical standing in the cell lineage of the presumptive 
precursors, despite Some clues. For example, Gata3, a marker 
of mature luminal epithelium also expressed in precursor 
cells of mammary primordia (Asselin-Labat ML, et al. Nat. 
Cell Biol. (2007), 9:201-209), is present in PCC but not in 
SCC (FIG. 6 and Table 4). This difference may be indicative 
of distinct cells-of-origin, also Suggested by the identification 
of distinct CISs. Differences in the expression of particular 
markers, such as CK5/14 and p63, also exist between SRC 
and the other two basal-like components (PCC and SCC). It is 
noted that the SRC, despite loss of E-cadherin (epithelial 
marker) and strong expression of Vimentin (mesenchymal 
cell marker; see FIG. 6), are presumably epithelial and not 
mesenchymal tumors that could be derived from an adenos 
quamous component by epithelial-mesenchymal transition 
(Cardiff R D, et al., The Mouse in Biomedical Research. 
(2007), Volume II. Diseases, Second ed., eds. Fox JG et al., 
(Elsevier, New York), pp. 581-622). 
Since the exact stages in the developmental progression 
from stem cells to differentiated luminal and myoepithelial 
cells remain largely undefined, a likely scenario accounting 
for the Kras tumor heterogeneity in conjunction with the 
hypothesis described above, is parallel transformation of 
three different cell types. There are three reasons for such a 
scenario. First, the originator of the Dunn A/B tumors is a 
fully committed luminal-type cell that can still respond to 
oncogenic stimuli without becoming apoptotic. Second, the 
Wap gene, and therefore cre, is expressed in bipotentalveolar 
progenitor cells of virgin and parous mice (Booth BW, et al., 
JCell Physiol. (2007), 212:729-736: Matulka LA, et al., Dev. 
Biol. (2007), 303:29-44), and also that a significant expansion 
of the Cd24"/Cd49' compartment containing mammary 
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bipotent progenitors/stem cells (Shackleton M, et al., Nature 
(2006), 439:84-88) occurs in Kras mice, it is speculated that 
the squamous cell carcinoma probably originates from Such 
cell precursors. Squamous metaplasia has been widely 
reported in mouse models of breast cancer, including MMTV- 5 
Wnt mice, in which progenitor cells are thought to be the 
target of oncogenic transformation (Li Y., et al., Proc. Natl. 
Acad. Sci. USA (2003), 100:15853-15858). In the context of 
this scheme, to account for Gata3 expression and the presence 
of a distinct CIS, it is proposed that a third cellof-origin, also 10 
bearing the CD24 and CD49f markers, gives rise to pale cell 
carcinoma. 
11. EXAMPLE 6 15 
Efficacy of Compounds 18 and 21 to Ameliorate 
Kras-induced Mammory Carcinomas 
The efficacy of compounds 18 “(NB3)' and 21 “(NB6) to 20 
ameliorate Kras-induced mouse mammary carcinomas was 
tested. While testing NB3 and NB6 (4 mice each), 2 controls 
were added (2 tumor-bearing mice treated with vehicle). The 
control data were pooled with the previous, and the new 
results are listed in Table 10: 
SEQUENCE LISTING 
<16 Os NUMBER OF SEO ID NOS: 4 
<210 
<211 
<212> 
<213> 
<22 Os 
<223> 
SEQ ID NO 1 
LENGTH: 21 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE; 
OTHER INFORMATION: Combined DNA/RNA molecule: 
sense Strand 
FEATURE; 
OTHER INFORMATION: 
<4 OOs SEQUENCE: 1 
caalugaguac aaculacc.gct t 
SEO ID NO 2 
LENGTH: 21 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE; 
OTHER INFORMATION: Combined DNA/RNA molecule: 
antisense strand 
FEATURE; 
OTHER INFORMATION: 
<4 OOs SEQUENCE: 2 
gcggulaguug uacucaulugt t 
SEO ID NO 3 
LENGTH: 21 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE; 
OTHER INFORMATION: Combined DNA/RNA molecule: 
duplex Scra sense strand 
FEATURE; 
OTHER INFORMATION: 
<22 Os 
<223> 
<4 OOs SEQUENCE: 3 
glucacaccga ulaagucacat t 
siRNA duplex R4 sense strand 
58 
TABLE 10 
Drug treatments 
Mice Glands Tumor volume 
Mouse Tumors (n) (n) per gland (mm) % Pb 
Vehicle 9 29 243.3 68.9 1OO 
NB3 4 15 20.9 10.8 6.5 <O.OOO1 
NB6 4 13 2.1 1.O O.9 <O.OOO1 
Mean S.E.M. 
Because of data skewness, in tumor volume comparisons between the drug treatments and 
the control (vehicle), probabilities (P) were calculated using Student's t-test after logarith 
mic transformation of the values to meet the distribution criterion of the test. 
If, on the basis of the new control data, the previous “9% 
tumor volume in comparison with the control” for PPP 
(7.3%) is normalized, it becomes 6.5%, i.e. NB3 has the same 
potency as PPP. Importantly, however, NB6 (compound 21) 
appears to be 7 times more potent. 
While the invention has been described with respect to 
specific examples including presently preferred modes of 
carrying out the invention, those skilled in the art will appre 
ciate that there are numerous variations and permutations of 
the above described systems and techniques that fall within 
the spirit and scope of the invention. 
Various publications are cited above, the contents of which 
are hereby incorporated by reference in their entireties. 
siRNA duplex R4 
21 
siRNA duplex R4 
siRNA duplex R4 antisense strand 
21 
scrambled control 
scrambled control duplex Scra sense strand 
21 
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<210s, SEQ ID NO 4 
&211s LENGTH: 21 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Combined DNA/RNA molecule: 
duplex Scra antisense strand 
22 Os. FEATURE: 
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- Continued 
scrambled control 
<223> OTHER INFORMATION: scrambled control duplex Scra antisense strand 
<4 OOs, SEQUENCE: 4 
ugugacuulau cqgugugact t 
We claim: 
1. A compound of formula I: 
Yi 
25 
30 
35 
wherein X, X, Y, Y and Z are independently hydrogen, a 
C-Cs alkyl, or C-C alkoxy group with the proviso that 
when X and X’ are H. Y.Y., and Z cannot all be OCH. 
2. The compound of claim 1 wherein X, X', Y.Y. and Z are 
hydrogen, methyl, or methoxy. 
3. The compound of claim 1 wherein 
X, X, Y, Y-H, and Z=OCH: 
X, X, Y, Z=H, and Y=OCH: 
X, X', Y—H, and Y, Z=OCH: 
X, X, Z=H, and Y.Y—OCH; or 
X, X,Y, Y-H, and Z=CH, 
40 
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4. A compound selected from the group consisting of 
OMe 
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-continued 
() 8. d 
OMe 
OMe 
OH 
MeO OMe 
5. The compound of claim 1 wherein the C-C alkoxy is a 
C-C alkoxy. 
6. A pharmaceutical composition comprising a compound 
of claim 1 and a pharmaceutically acceptable carrier thereof. 
7. A pharmaceutical composition comprising a compound 
of claim 2 and a pharmaceutically acceptable carrier thereof. 
8. A pharmaceutical composition comprising a compound 
of claim 3 and a pharmaceutically acceptable carrier thereof. 
9. A pharmaceutical composition comprising a compound 
of claim 4 and a pharmaceutically acceptable carrier thereof. 
10. A pharmaceutical composition comprising a com 
pound of claim 5 and a pharmaceutically acceptable carrier 
thereof. 
  
  
  
  
